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CHAPTER I

INTRODUCTION

Stress has profound effects on neuroendocrine function,
increasing plasma corticosterone and prolactin levels, and plasma renin
activity (PRA).
play an

Neurons in the hypothalamic paraventricular nucleus (PVN)

important

role

behavioral functions.

as

integrators

of

endocrine,

autonomic

and

The purpose of this dissertation research project

was to investigate the role of neurons in, and afferents to, the PVN in
mediating stress-induced neuroendocrine responses, specifically increased
PRA, plasma renin concentration (PRC), and corticosterone levels.
Sprague-Dawley rats were used for

these

experiments.

The

Male

stressor

consisted of a conditioned emotional (fear) response paradigm, which has
been shown to cause increases in renin and corticosterone secretion.
this

paradigm,

each

rat

receives

a

footshock

10 minutes

following

placement in a chamber, and then was returned to his home cage.
procedure is repeated for three consecutive days.

In

This

On the fourth day,

instead of receiving shock 10 minutes after being placed in the test
chamber, the rat is removed and sacrificed by decapitation.
was collected for hormone assays.

Trunk blood

The experimental control rats were

treated identically to rats in the treatment group with the exception that
shock was not administered at any time.

1

2
1. Effect of Electrolytic PVN Lesions on Stress-Induced Renin and
Corticosterone Secretion.

Bilateral electrolytic lesions in the PVN

prevented the stress-induced increase in PRA,
In contrast,

levels.

electrolytic

lesions

PRC and corticosterone
in the

thalamic nucleus

reuniens, dorsal and caudal to the PVN, did not prevent the stress-induced
increase in either PRA, PRC or corticosterone levels.

Since the majority

of the diencephalic corticotropin releasing factor

(CRF) neurons are

located in the parvocellular subnuclei of the PVN, it is not surprising
that electrolytic PVN lesions prevented the stress-induced increase in
corticosterone secretion.

However, the finding that the stress-induced

increases in PRA and PRC were also prevented was unexpected.

2. Effect of Ibotenic Acid Lesions of Cells in the PVN on StressInduced Renin and Corticosterone Secretion.

Ibotenic acid is a selective

neurotoxin that destroys cell bodies while leaving fibers of passage
intact.

To determine whether cell bodies in the PVN or fibers of passage

mediate stress-induced increases in PRA, PRC and corticosterone levels,
the cells in the PVN were selectively destroyed by injection of ibotenic
acid.

The corticosterone, PRA and PRC responses to stress were blocked

by ibotenic acid injection.

These observations suggest that neuronal cell

bodies in the PVN mediate the stress-induced increase in PRA, PRC and
corticosterone.

3.

Effect of 6-Hydroxydopamine-Induced Lesions

Stress-Induced Renin and

Corticosterone

Secretion.

in the
Since

PVN on

the

data

indicated that cell bodies in the PVN mediate stress-induced renin and

3

corticosterone secretion,

and the PVN is known to have an extensive

catecholaminergic innervation,

the next approach was

to determine if

catecholaminergic innervation of PVN neurons plays an important role in
the neuroendocrine response to stress.

This was accomplished by injection

of the neurotoxin 6-hydroxydopamine (6-0HDA) into the PVN.

6-0HDA is

taken up by the catecholaminergic nerve endings resulting in degeneration
of these nerve terminals.

Lesion placement and damage to noradrenergic

nerve terminals was verified by immunocytochemical methods,
antibody against dopamine E-hydroxylase.
the

stress-induced

increase

in

PRA,

using an

The 6-0HDA injections prevented
PRC

and

corticosterone

levels,

suggesting that intact catecholaminergic afferents to the PVN are critical
for the stress-induced increase in renin and corticosterone secretion.

4.

Effect

of Microinj ection of

the

E-Adrenoceptor Antagonist

Sotalol into the PVN on Stress-Induced Renin and Corticosterone Secretion.
The results from the experiment with 6-0HDA suggest that catecholaminergic
nerve terminals in the PVN are involved in mediating the effect of stress
on renin and corticosterone secretion.

In previous studies,

the H.-

adrenoceptor antagonist propranolol attenuated the stress- induced increase
in PRA.

Since propranolol is known to cross the blood-brain barrier, it

is possible that &-receptors, located in the PVN, mediate the effect of
stress on renin and corticosterone secretion.

To test this hypothesis,

the H.-adrenoceptor antagonist sotalol was microinj ected into the PVN.
Sotalol prevented the stress-induced increase in corticosterone levels,
but did not attenuate the stress-induced increase in PRA or PRC.

The

results suggest that a catecholaminergic input to cells in the PVN mediate

4
the effect of stress on renin and corticosterone secretion.

Furthermore,

stress-induced increases in corticosterone levels are mediated via &receptors, whereas stress-induced increases in PRA and PRC are mediated
by different receptors.

CHAPTER I I

LITERATURE REVIEW

A. RENIN
1. Introduction
The renin-angiotensin system plays a role in the maintenance of
sodium balance (Parfrey et al., 1981) and the regulation of blood pressure
and volume (Fujii and Vatner, 1985).

Renin is the enzyme responsible for

the conversion of angiotensinogen to angiotensin I
AI

(AI), a decapeptide.

is further converted to the octapeptide angiotensin II

peptidyl dipeptidase, converting enzyme.

(All) by a

This reaction is slow in vitro,

but rapid in vivo due to the activity of tissue-bound converting enzyme
present on the luminal aspect of vascular endothelial cells throughout the
body (Caldwell et al., 1976).
synthesis of All.

Renin is the rate-limiting enzyme in the

All is the physiologically active component of the
All causes vasoconstriction by a

system and a potent pressor agent.

direct action on vascular smooth muscle

(Fujii and Vatner,

indirectly via the sympathetic nervous system (Peach

1985)

and

et al., 1971).

2. Description of Renin
Renin is a glycoprotein with a molecular weight of about 40,000
(Galen et al., 1979).
and Pratt,

1986)

Specifically, it is an aspartyl proteinase (Dzau

that cleaves

a

leucine-leucine peptide bond between

5

6

residues 10 and 11 of angiotensinogen.

Renin has a circulation half-

life of 4-15 minutes (Michelakis and Mizukoshia, 1971; Gordon and Sullivan, 1969; Gutman et al., 1973; Oates et al., 1974; Oparil et al., 1970;
De Vito et al.,

1977) and is metabolized by the liver and kidneys.

Inactive forms of renin (prorenin and activation intermediates) have been
found in the plasma of humans (Leckie, 1981), dogs (Wilczynski and Osmond,
1983) and rats (Osmond et al., 1982).

Prorenin is a circulating, high

molecular weight form of renin with no
(Sealey et al.,

1979;

intrinsic enzymatic activity

lnagami and Murakami,

following bilateral nephrectomy was

1980).

Prorenin release

reported to be under F..-receptor

regulation (Wilczynski and Osmond, 1986).

Nielsen and Poulsen (1988)

reported that the kidney is the main source of inactive renin.

3. Physiological Aspects of the Angiotensins
a. Angiotensinogen (renin substrate)
The

glycoprotein angiotensinogen

60,000) is the substrate for renin.
is the liver.

(approximate molecular weight

The main source of angiotensinogen

lmmunocytochemical studies (Richoux et al.,

1983) and

Northern Blot analysis with complementary mRNA sequences for angiotensinogen (lngelfinger et al., 1986) have shown that the liver contains and
synthesizes angiotensinogen.

Angiotensinogen is widely distributed in the

blood and other extracellular fluids (Reid and Ramsay, 1975; Horky et al.,
1971; Keeton and Campbell, 1980).
Plasma levels of angiotensinogen can be decreased by adrenalectomy
(Carretero and Gross, 1967), hypophysectomy (Goodwin et al., 1970) and

7

diseases that impair liver function (Ayers, 1967).

The administration of

glucocorticoids, mineralocorticoids and sodium replacement can prevent the
decrease in angiotensinogen levels produced by adrenalectomy (Nasjletti
and Masson, 1969).

Nephrectomy increases plasma levels of angiotensinogen

(Hiwada et al., 1976; Carretero and Gross, 1967; Bing and Poulsen, 1969).
This increase is thought to be mediated by adrenocortical steroids.
Eggena and Barrett (1988) demonstrated an additive effect of nephrectomy
and

dexamethasone

on

the

stimulation of

renin

substrate

secretion.

Freeman and Rostorfer (1972) observed that adrenalectomy caused a 70%
reduction of the increase in plasma angiotensinogen caused by nephrectomy.
Surgical stress, which stimulates the release of adrenocortical steroids,
also increases plasma levels of angiotensinogen for several days in
rabbits (Campbell et al., 1973; Romero et al., 1970; Morris et al., 1977).
These studies suggest that an intact pituitary-adrenal axis is necessary
for adequate substrate production.

b. Angiotensin I (AI)
The amino terminal decapeptide AI is cleaved from angiotensinogen
by renin in the blood.

Angiotensin I has been reported to act in a

similar manner to All with respect to the adrenal medulla (stimulating
the release of catecholamines) and the central nervous system (inducing
thirst), but with lower potency (Fitzsimons, 1971; Peach, 1974).

c. Angiotensin II (AII)
All has many physiological effects, all of which are involved in
the maintenance of blood pressure and plasma volume.

All is a potent

8
pressor agent, acting directly on the vascular smooth muscle to cause
vasoconstriction (Skeggs et al., 1956) and indirectly, via the sympathetic
nervous system (Peach et al., 1971; Scroop et al., 1971).

Similarly, All

increases cardiac contractility in vitro by a direct action on the
myocardium and indirectly via norepinephrine release from the cardioaccelerator nerves (Blumberg et al., 1975).

All acts on the peripheral

arterioles to maintain arterial pressure in low cardiac output states
(Davis and Freeman, 1976).
All stimulates the secretion of aldosterone by a direct action on
the zona glomerulosa of the adrenal cortex (Bartter et al., 1961; Biron
et al., 1961).

Blockade of All receptors decreases aldosterone production

to nondetectable levels (Davis and Freeman, 1976).

All also stimulates

vasopressin secretion when administered intraventricularly in rats and
dogs (Share, 1979; Keil et al., 1975) or intravenously in conscious dogs
(Reid et al., 1982; Bonjour and Malvin, 1970), conscious rats (Knepel and
Meyer, 1980) and humans (Uhlich et al., 1975; Padfield and Morton, 1977).
Aldosterone and vasopressin act at the distal tubules of the kidney to
increase sodium and water reabsorption, respectively.

Together, they act

to restore blood pressure and volume in response to the physiological
stress of hypotension, hemorrhage and/or hypovolemia.
All inhibits renin release when it binds to the juxtaglomerular
(JG) cells (Dzau and Pratt, 1986), and increases the concentration of
angiotensinogen in the plasma of dogs (Blair-West et al., 1974; Beaty et
al., 1976) and rats (Nasjletti and Masson, 1973; Khayyall et al., 1973).
All

also

stimulates

hepatocytes

(Klett

secretion of angiotensinogen in vitro
and Hackenthal,

1987).

It

is

likely

from rat
that

the

9
stimulation of angiotensinogen by All occurs via enhanced glucocorticoid
secretion.

All stimulates glucocorticoid secretion by a direct action on

the adrenal cortex

(Kaplan,

1965)

and indirectly by potentiating the

effect of CRF on ACTH secretion (Keller-Wood et al.,
Yates, 1977; Spinedi and Negro-Vilar, 1983).
that All

stimulates

1986; Maran and

Reid et al. (1978) suggested

angiotensinogen production to provide a

positive

feedback mechanism to prevent lack of substrate supply during periods of
elevated renin secretion.

4. Regulation of Renin Secretion
a. Introduction
Renin

secretion

from

the

kidney

neural, chemical and mechanical factors.

is

regulated by

a

number

of

In general, factors that cause

a decrease in either renal perfusion pressure, blood volume or plasma
sodium concentration will stimulate renin secretion.
Renin is secreted by the granular juxtaglomerular cells located in
the afferent arterioles of the kidney (Taugner et al., 1979; Taugner et
al.,

1984).

The juxtaglomerular cells are in close proximity to the

macula densa, a specialized portion of the distal tubule that is sensitive
to changes in sodium reabsorption across the tubular epithelium.
macula densa monitors
relays

the

message

to

Studies by ltoh et al.
of A1 receptors,

the

The

ionic environment in the tubular fluid and

either

increase

or

decrease

renin

secretion.

(1985) suggest that adenosine, via the activation

may be a

signal from the macula densa to the juxta-

glomerular cells to inhibit renin release.

It is reported that a decrease

in the amount of sodium (Churchill et al., 1978), potassium (Shade et al.,
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1972) or chloride (Rostand et al., 1985) that crosses the macula densa
cells will stimulate renin secretion.
Renin secretion is also stimulated by a decrease in renal arterial
pressure.

The idea that a "pressor substance" (later to be known as

renin) was secreted in response to a decrease in renal blood flow was
first postulated by Goldblatt et al.

(1934).

This idea was further

developed by Tobian et al. (1959) who suggested the existence of a renal
baroreceptor that was responsible for the inverse relationship between
blood pressure and renin secretion.
Studies by Fahri et al. (1982) have shown that stimulation of renin
secretion following a decrease in renal arterial pressure occurs via an
intrarenal baroreceptor interacting with a

renal B-receptor.

Their

studies have demonstrated that elevating plasma epinephrine concentration
without changing blood pressure does not increase plasma renin activity.
However, if epinephrine secretion accompanies a stimulus (e.g., hemorrhage) which also lowers blood pressure,
increased.

then renin secretion will be

This system allows for plasma renin activity to be either

stimulated or unaffected by high physiological levels of circulating
epinephrine, depending on whether or not a hypotensive threat is involved.

b. Role of the Sympathetic Nervous System in Renin Secretion
The

sympathetic

innervation

of

the

rat

kidney

consists

of

sympathetic cell bodies in paravertebral (thoracic T6 through lumbar L4)
and

prevertebral

(renal,

(Sripairoj thikoon and Wyss,

greater
1987).

splanchnic,

and

celiac)

ganglia

Stimulation of the renal nerves
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increases renin secretion (Di Bona, 1985; Blair et al., 1985).
stimulatory effect is mediated,

This

at least in part, via norepinephrine

released from the endings of the postganglionic sympathetic neurons that
innervate

the

kidneys

(Johnson et al.,

1971;

Taber

et al.,

Circulating epinephrine can also stimulate renin secretion.

1976).

The effect

of stimulation of the renal nerves can be enhanced by activating beta (,8)
receptors (Vander, 1965).

Catecholamines are believed to stimulate renin

secretion via a ,B-adrenergic mechanism since /3-antagonists have been shown
to inhibit their effect both in vivo (Loeffler et al., 1972; Pettinger and
Keeton, 1975) and in vitro (Weinberger et al., 1975; Vandongen et al.,
The

1973).

renin

stimulating

potency

profile

is

isoproterenol

>

epinephrine > norepinephrine according to studies in conscious dogs by
Johnson et al. (1979).
(1981)

suggest that

Studies by Healy et al. (1985) and Osborn et al.
the

sympathetic nervous

system stimulates renin

release by activating B1 receptors on the juxtaglomerular cells.

c. Role of Extra-Renal Beta Receptors in Renin Secretion
Although

there

is

evidence

supporting

intrarenal

/3 receptor

regulation of renin secretion, this does not exclude a role of extrarenal
/3-adrenergic receptors that provide a powerful stimulatory effect on renin
secretion.

For example, Reid et al. (1972) observed increases in plasma

renin activity and renin secretion following isoproterenol infusion into
the femoral artery of dogs.
with an aortic clamp.

Renal perfusion pressure was kept constant

However, infusion of the same doses of isoproter-

enol into the renal artery had no effect on plasma renin activity or renin
secretion, suggesting that an extrarenal ,B receptor mechanism is involved
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in regulating renin secretion.

Johnson et al.

(1979) obtained similar

results with infusion of epinephrine and norepinephrine into the inferior
vena cava (IVG)
resulted in a

and renal artery.
3. 5-fold increase

Epinephrine infusion into the IVG
in plasma renin activity while IVG

infusion of norepinephrine resulted in a 1.5-fold increase in plasma renin
activity.

Infusion of epinephrine or norepinephrine directly into the

renal artery to achieve similar arterial concentrations resulted in no
increases in plasma renin activity.

Fahri et al. (1982) suggested that

the effect of epinephrine in the intact conscious dog can be explained as
the combination of an extrarenal and intrarenal action.

The extrarenal

event is a generalized vasodilation that results in a drop in blood
pressure which is sensed by the renal baroreceptor.
is mediated through intrarenal

/3 receptors which affect the stimulus-

response curve of the renal baroreceptor.
location of the extrarenal

The intrarenal action

At the present time the

/3 receptor has not been established.

d. Role of Brain Serotonin (5-HT) Neurons in Renin Secretion
In 1980, Zimmermann and Ganong demonstrated that injection of the
5-HT precursors 5-hydroxytryptophan (5-HTP) or tryptophan to anesthetized
dogs increased plasma renin activity.

In humans, the 5-HT precursor L-

tryptophan was reported to increase renin secretion (Modlinger et al.,
1979), and the 5-HT antagonist cyproheptadine inhibited the secretion of
renin induced by furosemide (Epstein and Hamilton, 1977).

In rats, the

5-HT releasers p-chloroamphetamine (PGA) and fenfluramine dose-dependently
increased plasma renin activity via release of 5-HT from serotonergic
nerve terminals (Van de Kar et al., 1981; 1985).

The 5-HT 2 antagonist
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LY53857 dose-dependently inhibited the increase in plasma renin activity
and plasma renin concentration following administration of fenfluramine
and MK-212, a 5-HT agonist, suggesting that stimulation of 5-HT2 receptors
enhances renin release (Lorens and Van de Kar, 1987).
The effect of PCA on plasma renin activity was prevented by either
pretreatment with

the

5-HT

synthesis

inhibitor p-chlorophenylalanine

(PCPA) or by a chemical lesion of the dorsal raphe nucleus with the 5-HT
neurotoxin,

5, 7-dihydroxytryptamine

(Van

de

Kar

et

al.,

1982).

A

mechanical lesion in the mediobasal hypothalamus, as well as posterolateral deafferentation of the hypothalamus (separating the hypothalamus
from the midbrain) also blocked the effect of PCA on plasma renin activity
(Karteszi et al., 1982).

Anterolateral section through the retrochias-

matic area was ineffective in blocking the effect of PCA on plasma renin
activity (Karteszi et al., 1982).

These results suggest that a serotoner-

gic pathway, with cells in the dorsal raphe nucleus in the midbrain and
terminals in the mediobasal hypothalamus, stimulates renin secretion.

1. Role of Beta Receptors in the Serotonergic
Stimulation of Renin Secretion
There is evidence for f3 receptor involvement in mediating the
serotonergic stimulation of renin secretion.

Van de Kar and Richardson

Morton (1986) demonstrated that the B1 and B2 antagonist sotalol and the
B1 antagonist atenolol prevented the increase in plasma renin activity
after the injection of PCA and fenfluramine.

These findings supported

those of Alper and Ganong (1984) who demonstrated that pretreatment with
the

sotalol

and propranolol prevented

the

increase

in plasma renin
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activity produced by PCA.
the

sympathetic

nervous

These studies suggested a possible role for
system

in mediating

the

increase

in

renin

secretion following the administration of 5-HT releasers.
However, in rats which were adrenal medullectomized and sympathectomized by chronic injections of 6-0HDA, there was no inhibition of the
PCA- and fenfluramine-induced increase in plasma renin activity.

Renal

norepinephrine content was reduced to undetectable levels, suggesting that
it is not likely that the serotonergic stimulation of renin secretion is
mediated via the sympathetic nervous system or adrenal catecholamines (Van
de Kar and Richardson Morton,

1986).

contradiction with the fact that the

These results

~-adrenergic

seem to be

in

receptor antagonists

sotalol and atenolol prevented the PCA- or fenfluramine-induced increase
in plasma renin activity.
et al.

However studies by Johnson (1984) and Johnson

(1979), as described earlier, provide evidence

that~

receptors

that mediate the increase in plasma renin activity are located outside the
kidney, suggesting an entirely different mechanism of stimulating renin
secretion.

In addition, many beta receptor antagonists are known to bind

to 5-HT receptors

(Middlemiss et al.,

1977) and it is possible that

sotalol and atenolol are present in sufficient concentrations in the brain
to block the 5-HT receptors and inhibit the serotonin-mediated increase
in plasma renin activity (Lemmer et al., 1985; Garvey and Ram, 1975).
summarize,

the

data suggest

that brain 5-HT neurons

regulate

To

renin

secretion via a mechanism that is not related to the autonomic sympathetic
nervous system or adrenal catecholamines.
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e. Role of the Hypothalamic Paraventricular Nucleus
in Renin Secretion
The PVN plays a role in neurogenic and genetic models of hypertension (Ciriello et al., 1984; Zhang and Ciriello, 1985).

The PVN is a

logical central site to influence renin secretion as it receives afferent
information from the baroreceptor region as well as having efferent
projections to the sympathetic areas of the spinal cord (Sawchenko and
Swanson, 1982).
Electrolytic lesions in the PVN have been shown to prevent the
increase in plasma renin activity produced by the 5-HT releasing drug PCA
as well as preventing the increase in plasma renin activity that follows
immobilization stress (Gotoh et al., 1987).

Previous studies (Gotoh et

al., 1985) demonstrated that bilateral knife cuts behind the hypothalamic
paraventricular nucleus (PVN) reduced the renin response to immobilization
and the gravitational stress of head-up tilting, suggesting a role for the
PVN in both stress-induced and 5-HT- stimulated renin secretion.
Electrical stimulation of the PVN in conscious rats
plasma renin activity in a frequency-related manner.

increased

There were no

significant changes reported in heart rate, mean arterial pressure or
renal vascular resistance at any of the frequencies that produced an
increase in plasma renin activity (Porter, 1986).

These results suggest

that neurons in the PVN stimulate renin secretion.
Additional studies by Porter (1988) demonstrated the relationship
between

renal

perfusion

pressure

and

plasma

continuous low-level stimulation of the PVN.

renin

activity

during

He found that for any given

16
decrease in renal perfusion pressure, the plasma renin activity increase
was greater during the ongoing PVN stimulation.

The effect of stimula-

tion of the PVN was prevented by both renal denervation and pretreatment
with propranolol.

These studies suggest that stimulation of the PVN

elicits increased responsiveness of the kidneys to decreases in renal
perfusion pressure, and that this effect is mediated via the sympathetic
nervous system.

f. Other Hypothalamic Areas Involved in Renin Secretion
The lateral and posterior hypothalamic areas have long been known
as

sites

where

pressor

responses

can

be

elicited

with

stimulation (Brody et al., 1986; Ciriello and Calaresu, 1977).

electrical
Therefore

it is not surprising that increases in plasma renin activity are also
observed following electrical stimulation of the lateral (Zanchetti and
Stella, 1975) and posterior (Natcheff et al., 1977) hypothalamus.

Unlike

the studies by Porter (1986) involving the PVN, these increases in plasma
renin activity were

accompanied by

required intact renal nerves.

increases

in blood pressure and

It is likely that the lateral and posterior

hypothalamus exert their cardiovascular effects through long descending
neuronal projections to the NTS (Kuypers et al., 1973) or ventrolateral
medulla (Brody et al., 1986).
Gotoh et al. (1987) reported that bilateral electrolytic lesions
of the ventromedial nucleus prevented

the

increase

in plasma renin

activity produced by each of the following stimuli: the 5-HT-releaser PCA,
immobilization, head-up tilt under inactin anesthesia, and a low-sodium
diet.

The authors hypothesize that the stimuli that increase plasma renin
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activity via the ventromedial nucleus

act by

increasing sympathetic

activity since the P-adrenergic receptor antagonist propranolol blocks the
renin response to PCA, immobilization and head-up tilt.

The PCA response

is also abolished by another P-adrenergic receptor antagonist, sotalol,
and by ganglionic blockade

(Alper and Ganong,

1984).

In addition,

stimulation of the ventromedial nucleus increases blood pressure (Bunag
and Inoue, 1985), while bilateral lesions of this nucleus prevent the
development of experimental hypertension (Brody and Johnson, 1980).

g. Extrahypothalamic Pathways Involved in Renin Secretion
Other central nervous system sites play a role in renin release.
Electrical stimulation of the ventrolateral medulla (Richardson et al.,
1974),

dorsal medulla

(Passo et al.,

1971)

and mesencephalic dorsal

periaqueductal grey (Ueda et al., 1967) produced increases in plasma renin
activity that were mediated via the renal nerves.

h. Renin and Angiotensin in the Brain
Administration

of

renin or All

into

the

cerebral

ventricles

stimulates vasopressin secretion (Keil et al., 1975), increases drinking
behavior and increases blood pressure
anterior

forebrain

and

nuclei

of

the

(Reid and Ramsay,
anteroventral

1975).

third

The

cerebral

ventricle (AV3V) play a role in the All-induced stimulation of drinking
behavior, vasopressin release and increased arterial pressure.

These

brain areas are richly innervated by catecholaminergic fibers arising from
cell bodies in the A2 area of the nucleus tractus solitarius, and other
brainstem regions involved with central cardiovascular regulation (Saper
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et al., 1983; Palkovits et al., 1974; Meldrum et al., 1984).

Bellin et

al. (1987) have shown that rats with 6-0HDA injections into the lateral
cerebral

ventricle

had

significantly

attenuated

drinking

and

blood

pressure responses following both central and systemic All administration.
Rats pretreated with desmethylimipramine (DMI) prior to injection of 60HDA

(to protect noradrenergic

terminals)

had no

response deficits following All administration.
role

for norepinephrine

thirst or pressor

These results suggest a

in mediating All-induced drinking and blood

pressure responses.
The

distributions

of

angiotensin

I

and

II,

angiotensinogen,

angiotensin-converting enzyme (ACE) and renin in the brain have been
studied

by

various

biochemical

and

irnrnunocytochemical

techniques

(Brownfield et al., 1982; Changaris et al., 1977; Fuxe et al., 1976; Fuxe
et al., 1980; Basso et al., 1982; Fischer-Ferraro et al., 1971), although
the physiological role for these substances is not clear.

Ganong et al.

(1979) suggested that All-like irnrnunoreactive material in the brain may
be involved in modulating the release and action of brain catecholamines.
The
debatable.

presence

of

a

brain

renin-angiotensin

system

is

highly

Fuxe et al. (1980) demonstrated renin-like irnrnunoreactivity

in the paraventricular, periventricular and supraoptic nuclei in the rat
and mouse.

Dabsys et al. (1988) demonstrated an increase in angiotensin-

converting enzyme activity levels in the amygdaloid complex following
bilateral destruction of the ventral noradrenergic pathway with 6-0HDA.
There

was

a

concomitant

increase

in

arterial

blood

pressure

that

significantly correlated with the ACE activity levels in the amygdala.
Studies in nephrectomized animals revealed All-like irnrnunoreactivity in
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brain tissue (Phillips and Stenstrom, 1983) and significant elevations in
angiotensinogen content in the hypothalamus and midbrain (Gregory et al.,
However, the All-like material from rat brain has been shown to

1982).

be different from authentic All by both gel filtration (Meyer et al.,
1982) and anion exchange HPLC techniques

(Pohl et al.,

1988).

These

studies indicated that the All-like material has a molecular weight of
5000

7000

(compared to

1046

for All)

and is

more polar but

less

positively charged than All.
Although

indirect

studies

suggest

the

presence

of

each

of

the

components of the renin-angiotensin system in the brain (Printz et al.,
1982) there is no evidence to support a functional brain renin-angiotensin
Brownfield

system.

et

al.

(1982)

have

demonstrated

that

although

angiotensin and converting enzyme immunoreactivities are present in the
brain,

they are not co-distributed,

suggesting that there is no brain

pathway for the formation of angiotensin.

i. Role of Brain Catecholamines in Renin Secretion
Norepinephrine in the brain was proposed to inhibit secretion of
renin

from

the

kidney

through

changes

in

sympathetic

activity

secretion of vasopressin (Blair et al. , 1977; Reid et al. , 1978).

and
The

antihypertensive drug clonidine is an alpha (a) 2 -agonist with a biphasic
effect on blood pressure: a transient increase followed by a prolonged
decrease.

lntracerebroventricular injection of clonidine lowers plasma

renin activity at a dose which is ineffective when given intravenously
(Reid

et

al.,

1975).

Blair

et

al.

(1977)

have

demonstrated

that

administration of L-DOPA to dogs pretreated with the peripheral decar-
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boxylase inhibitor carbidopa resulted in a drop in blood pressure and an
inhibition of renin secretion.

Since this treatment also increases brain

catecholamine content, this study suggests that catecholamines formed from
L-DOPA can act within the central nervous system to cause a decrease in
renin secretion.

In this study the decrease in plasma renin activity was

dependent upon the presence of the renal nerves.
The 5-HT releaser fenfluramine has a biphasic effect on plasma
renin activity: an initial increase followed by a sustained decrease.
Studies by Van de Kar et al. (1985) suggested that the initial increase
in plasma renin activity following fenfluramine administration is mediated
via release of serotonin, while the delayed, long-lasting suppression of
plasma renin activity is mediated via a catecholaminergic mechanism.
However,

the long-term suppression of plasma renin activity following

fenfluramine administration is not dependent on the peripheral sympathetic
nervous system, as it was not prevented by adrenal enucleation combined
with 6-0HDA-induced sympathectomy

(Van de Kar et al.,

1988).

To

determine whether a 2 -adrenoceptors mediate the suppressive effects of
fenfluramine, the a 2-antagonists yohimbine and rauwolscine were injected
prior to fenfluramine administration.

Neither a 2 -antagonist prevented the

long-term suppressive effect of fenfluramine on plasma renin activity or
plasma renin concentration.

The data suggest that fenfluramine does not

inhibit renin secretion by activating a 2-adrenoceptors in the CNS.

This

is in contrast to clonidine and a-methyl DOPA, which inhibit sympathetic
outflow to the kidneys through activation of central a 2-adrenoceptors.
Privitera et al. (1979) have shown that low doses of intracisternally-injected propranolol produced dose-dependent decreases in plasma
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renin activity and mean arterial pressure (MAP), whereas identical doses
given intravenously had no significant effect on plasma renin activity or
MAP.

A concomitant reduction in circulating norepinephrine levels was

also seen. This study suggests that propranolol could be acting at a
~-adrenergic

central

site to suppress renin release.

It is clear that central catecholamines play a role in mediating
the suppression of plasma renin activity, but the site(s) of action and
type of receptors involved have yet to be identified.

B. CORTICOSTERONE
1. Introduction
In 1856 Brown-Sequard discovered that the adrenal glands are essential
to life.

By the 1930's it became clear that the adrenal cortex is the

source of

two vital classes

of hormones:

one,

the

glucocorticoids,

regulate carbohydrate and protein metabolism, and the ability to tolerate
prolonged stress (Selye, 1946; Selye, 1943; Cori and Cori, 1927; Britton
and Silvette,

1931;

Long et al.,

1940).

The

second class

is

the

mineralocorticoids, which control water and electolyte metabolism and the
ability of the kidney to reabsorb sodium (Loeb et al., 1933; Harrop et
al., 1933).

Aldosterone is the primary salt-retaining hormone of the

adrenal cortex and is synthesized in the glomerulosa layer of cortical
cells.

Cortisol (in humans) and corticosterone (in rats) are the main

glucocorticoids secreted by the adrenal gland and are synthesized in the
fasciculata layer.

The fasiculata layer of cells in the adrenal cortex

is stimulated by adrenocorticotropin hormone (ACTH) from the anterior lobe
of the pituitary gland (Li et al., 1943; Sayers et al., 1943).

Ingle et
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al.,

(1938)

found that ACTH secretion from the anterior pituitary is

inhibited by secretions of the adrenal cortex.

The role of the hypothal-

amus in integrating stimulatory and inhibitory inputs to the adenohypophysis was studied by Harris (1948) and Rasmussen (1938).

Characteriza-

tion of the hypothalamic factor that stimulates corticotropin secretion
(CRF) was completed by Vale et al. (1981).

2. Corticotropin-Releasing Factor (CRF)
CRF from ovine hypothalamic tissue is a 41-amino acid peptide that
releases ACTH and

~-endorphin

from anterior pituitary cells (Vale et al.,

1981; Plotsky, 1985; Rivier et al., 1983; Rivier and Vale, 1983).
peptide is 5-10 times more potent in releasing ACTH and
vasopressin,

This

~-endorphin

than

which was originally thought to act as a corticotropin

releasing factor (Saffran and Schally,

1977).

Swanson et al.

(1983)

described the localization of CRF immunoreactive cells and fibers in three
distinct systems in the rat brain.
paraventricular nucleus (PVN).

The first group is in the hypothalamic

Approximately 2,000 CRF-stained cells are

found in each of the eight subdivisions of the PVN, although most (80%)
of the cells are concentrated in the parvocellular division (especially
the periventricular and medial parts), and about 15% are found in the
magnocellular division where oxytocinergic cells predominate.

These CRF-

containing neurons are the only ones that demonstrated increased staining
intensity following adrenalectomy.

The second group of CRF-containing

neurons are involved in mediating autonomic reponses.

They include the

central nucleus of the amygdala, bed nucleus of the stria terminalis,
substantia innominata,

lateral hypothalamic area,

medial and lateral
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preoptic

areas,

central

periaqueductal

grey,

laterodorsal

tegmental

nucleus, locus coeruleus, dorsal vagal complex, parabrachial nucleus and
regions containing the Al and AS catecholamine cell groups.

The third

group of CRF- immunoreactive cells are found in the cerebral cortex,
especially layers II and III of the neocortex, and limbic regions such as
the cingulate gyrus,

prefrontal areas and areas bordering the rhinal

fissure (Swanson et al., 1983).

CRF-like immunoreactive neurons were also

observed in the cerebellum and spinal cord (Olschowka et al.,

1982).

Outside the central nervous system, CRF-like immunoreactivity has been
found in endocrine cells of the pancreas and gastrointestinal system, also
in the liver, pituitary,

adrenal,

lung and placenta (Petrusz et al.,

1985).
The parvocellular neurons of the PVN contain CRF (Merchenthaler et
al., 1982; Liposits et al., 1983), which is transported along axons to the
median eminence where it is released into the hypophyseal portal vessels.
Makara et al. (1981) have shown that the CRF fibers in the stalk-median
eminence region either originate from or run through the PVN.

In the

pituitary gland, CRF is then bound to specific membrane receptors of ACTHcontaining cells (Wynn et al., 1984; Leroux and Pelletier, 1984).

ACTH

release is stimulated which, in turn, increases steroid hormone production
in the adrenal cortex.

The glucocorticoids then exert negative feedback

effects on both the hypothalamus (Yates and Urquhart, 1962) and anterior
pituitary (Russell et al., 1969; Mulder and Smelik, 1977) via glucocorticoid receptors (Gustafsson et al., 1983).

ACTH immunoreactive fibers

are found in most parts of the parvocellular division of the PVN and in
the oxytocinergic cells of the magnocellular division (Sawchenko et al.,
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1982; Swanson and Sawchenko, 1983).
Afferent connections to CRF neurons include presynaptic boutons
containing immunoreactive ACTH 1-39
(Liposits et al.,

1985),

control of CRF release.

(Liposits et al.,

1985)

and CRF

suggesting an autoregulatory process in the

Parvocellular CRF neurons also receive input from

magnocellular neurons in the same nucleus (Leranth et al., 1983) and send
processes to these magnocellular elements (Liposits et al., 1985).

CRF

neurons have been shown to have angiotensin II reactivity in adrenalectomized, colchicine-treated rats (Lind et al., 1985).
Rivier

and

Vale

(1983)

suggested

that

vasopressin

may

act

synergisticallywith CRF under certain physiological conditions to promote
ACTH secretion.

In addition, in vitro studies have shown that vasopressin

acts directly on the anterior pituitary corticotropes to stimulate ACTH
secretion (Vale et al.,

1983).

Together,

these results suggest that

vasopressin may act synergistically with CRF under certain physiological
conditions to promote ACTH secretion.
Sawchenko (1987) demonstrated that adrenalectomy (ADX) enhanced
both CRF and vasopressin immunoreactivity suggesting that they may be
colocalized in parvocellular neurosecretory neurons of the PVN.

Other

studies support this observation (Tramu et al., 1983; Kiss et al., 1984;
Sawchenko et al., 1984; Piekut and Joseph, 1985).

Dual immunocytochemical

studies have shown the co-localization of CRF and vasopressin in the
parvocellular neuronal perikarya in the

PVN.

In general, CRF immunos-

tained cells are concentrated in the medial parvocellular part of the PVN,
while the vasopressin neurons are predominantly in the magnocellular part
of the PVN.

However,

in adrenalectomized, colchicine-treated rats, a
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dense accumulation of vasopressin-imrnunoreactive cells were seen in the
medial parvocellular part of the PVN, in a similar distribution to that
seen for CRF- containing cell bodies (Piekut and Joseph, 1986).

Extra-

hypothalamic sites of ADX-enhanced CRF imrnunoreactivity included the
cerebral cortex, arnygdala and the bed nucleus of the stria terminalis.
These extra-hypothalamic sites contained no vasopressin imrnunoreactivity
colocalized with the CRF (Sawchenko, 1987).

Hypophysectomy as well as ADX

has been shown to enhance CRF imrnunostaining in PVN cell bodies (Bugnon
et al., 1983; Merchenthaler et al., 1983; Paull and Gibbs, 1983; Swanson
et al., 1983).

Sawchenko (1987) reported that hypophysectomy produced

results comparable to ADX-enhanced CRF and vasopressin staining in the
PVN.

Low doses of dexamethasone attenuated and high doses prevented the

ADX-induced enhancement of CRF and vasopressin imrnunoreactivity, with the
adrenal

dexamethasone > corticosterone >

steroid potency profile as

deoxycorticosterone > aldosterone.

These results suggest that adrenal

steroids, particularly glucocorticoids, play a primary role as regulators
of peptide expression.

3. Other Factors Affecting ACTH Release
Other neuropeptides that stimulate the release of ACTH include
angiotensin II

(All)

(Ramsay et al.,

1978;

Steele et al.,

1981) and

oxytocin (Beny and Baertschi, 1980; Pearlmutter et al., 1974).
dose-response

studies

by

Spinedi

and Negro-Vilar

(1983)

In vitro

ranked

the

corticotropin-releasing activity as follows: CRF > vasopressin > oxytocin

> AII.

The stimulatory effects of AII may involve the stimulation of AII

receptors in the anterior pituitary (Hauger et al., 1982; Mukherjee et
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al., 1982) or the hypothalamic PVN (Saavedra et al., 1986).

The density

of the All binding sites in the PVN have been shown to increase following
repeated immobilization stress

(Castren and Saavedra,

1988).

It is

possible that All receptors in the PVN play a role in modulating stressinduced corticosterone secretion.

4. Role of Brain Catecholamines in Corticosterone Secretion
a. Introduction
In general, the ascending noradrenergic pathways appear to relay
afferent visceral information to the forebrain (Cunningham and Sawchenko,
1988).

There has been considerable controversy as to whether catechol-

amines play an excitatory or inhibitory role in corticosterone secretion.
Norepinephrine and/or epinephrine have been implicated as stimulators of
the secretion of virtually every anterior pituitary hormone (Sawchenko and
Swanson, 1982).

With respect to ACTH secretion, brain catecholamines were

originally postulated to have an inhibitory role (van Loon et al., 1971;
Weiner and Ganong, 1978; Cuello et al., 1973; Scapagnini et al., 1970).
However,

in recent years

more

accurate

and reliable

anatomical

and

pharmacological studies suggest a stimulatory role for catecholamines in
corticosterone secretion (Szafarczyk et al., 1985; Feldman et al., 1988;
Alonso et al., 1986; Guillaume et al., 1987).

b. Anatomical Evidence
The
nucleus

predominantly noradrenergic

of the

solitary tract

(NTS)

(Sawchenko
sends

and Swanson,

fiber projections

1981)
to

the

parvocellular PVN, substantia innominata, central nucleus of the amygdala
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and bed nucleus of the stria terminalis (Ricardo and Koh, 1978), all of
which contain CRF-stained cells (Swanson et al., 1983).

Swanson et al.

(1983) suggested that the nucleus of the solitary tract, which receives
direct vagal and glossopharyngeal afferents (Beckstead and Norgren, 1979)
could serve as a major relay point of visceral sensory information to CRF
cell bodies in the basal forebrain.

Likewise the parabrachial nucleus,

which receives a large input from the NTS (Norgren, 1978), and the locus
coeruleus also project to many of the sites that contain CRF-immunoreactive cell bodies, including the parvocellular PVN, the bed nucleus of the
stria terminalis and the central nucleus of the amygdala.

These nuclei

may also be involved in the relay of visceral sensory information to CRF
cell bodies (Swanson et al., 1983).
Another

fiber

projection

is

described

from

the

predominantly

noradrenergic cells in the Al region of the ventrolateral medulla (which
receives an input from the NTS) to the magnocellular (vasopressinergic)
and parvocellular PVN.

Reciprocal connections have also been described

from the parvocellular PVN to the dorsal vagal complex and spinal cord
(Hosoya and Matsushita, 1979; Swanson and Kuypers, 1980).

Electrophysio-

logical studies by Kannan and Yamashita (1985) have also demonstrated
reciprocal connections between neurons in the NTS region and the PVN.
Studies by Skofitsch et al. (1985) have demonstrated binding sites for CRF
in sensory areas of the rat hindbrain and spinal cord, specifically in the
posterior part of the NTS, the substantia gelatinosa nervi trigemini and
laminae I and II of the spinal cord.

Since these areas are rich in nerve

endings of primary sensory neurons, this observation suggests a possible
role for CRF in mediating peripheral sensory processes.
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Cunningham and Sawchenko (1988) used an immunofluorescence doublelabeling procedure to determine which anterogradely labeled fibers and
terminals in the PVN also displayed dopamine P-hydroxylase immunoreactivity, indicating the presence of catecholaminergic neurons.

Specifical-

ly, projections from the Al (caudal ventrolateral medulla) region were
found to synapse on magnocellular vasopressinergic neurons in the PVN,
while projections from the A2 (medial part of the NTS) region were located
primarily

throughout

the

parvicellular

division

of

the

PVN.

The

projections were the most dense in the dorsal medial parvicellular region,
which

is known to

neurons.

contain a

large population of CRF- immunoreactive

A less-dense projection was found in the magnocellular division
The A6

of the PVN.

(locus coeruleus) projections were found almost

exclusively in the parvicellular division of the PVN, specifically in the
periventricular zone, which contains dopamine, somatostatin and thyrotropin-releasing
anatomical

hormone-containing

evidence

that

neurons.

These

the noradrenergic

cells

findings

provide

in the medial NTS

innervate CRF-immunoreactive cells in the PVN.
Liposits

et

al.

(1986)

showed

that

PNMT-immunoreactive

axon

terminals have synaptic connections with dendrites, somata and spinous
structures of CRF-immunoreactive neurons.

The parvocellular subnuclei

demonstrated a more intense adrenergic innervation than the magnocellular
subnuclei.

The mammalian anterior pituitary does not receive catechol-

aminergic innervation, unlike the neural and intermediate lobes which
receive noradrenergic and dopaminergic innervation (Bjorklund et al.,
1967; Saavedra et al., 1975).
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c. Role of the Ventral Noradrenergic Bundle in
Corticosterone Secretion
The

ventral

noradrenergic

bundle

(VNAB)

originates

from

the

medullary Al and A2 cell groups, and the pontine locus coeruleus.

It

extensively innervates the hypothalamus, conveying most of the catecholaminergic innervation to the PVN (Moore and Bloom, 1979; Palkovits, 1981;
Swanson and Sawchenko, 1980).

The VNAB is thought to be the source for

the noradrenergic modulation of ACTH secretion (Szafarczyk et al., 1985;
Feldman et al., 1988).
cell groups

Also, afferents from the epinephrine-containing

(Cl-C3) reach the hypothalamus via the VNAB (Ungerstedt,

1971).
Injections of 6-0HDA into the VNAB significantly reduced CRF levels
in hypophysial portal blood

(HPB)

as well

as

producing significant

depletion of hypothalamic norepinephrine and epinephrine
al., 1987).

(Guillaume et

Similar results were obtained by Eckland et al. (1988), who

found that 6-0HDA injections into the VNAB or the lateral ventricles
caused a reduction of HPB CRF concentration.

However, HPB norepinephrine

was reduced only with the i.c.v. 6-0HDA injections and was unchanged in
the VNAB-lesioned group.
Further support for a stimulatory role of norepinephrine in CRF
secretion is provided by Plotsky (1987).

The increase in hypophysial-

portal immunoreactive CRF (irCRF) following electrical stimulation of the
VNAB

was

prevented by

i.c.v.

pretreatment with

antagonist corynanthine, but not by the
olol.

~-adrenergic

the

a 1 -adrenoceptor

antagonist propran-

Corynanthine also blocked the dose-dependent increases in irCRF
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following

icv administration of norepinephrine

(0.1-5.0

nmol).

In

contrast, 5 nmol or greater doses of norepinephrine resulted in a dosedependent inhibition of irCRF release that could be blocked by propranolol, but was unaffected by corynanthine.

This suggests that low doses

of norepinephrine stimulate CRF release via an a-receptor mechanism,
whereas higher doses of norepinephrine inhibit CRF release via a &receptor.

d. Stimulation of CRF/Corticosterone Secretion by Epinephrine
and Norepinephrine
Microinjections

of

norepinephrine

(40

nmoles)

significantly increased serum corticosterone levels.

into

the

PVN

Epinephrine (40

nrnoles) microinjections into the PVN were even more efficacious than
norepinephrine in increasing serum corticosterone levels, whereas dopamine
(40 nrnoles) had no effect (Leibowitz et al., 1986).
Intravenous infusion of either !-epinephrine or the P-adrenoceptor
agonist 1-isoproterenol into pentobarbital anesthetized rats resulted in
a dose-dependent increase in plasma corticosterone levels.
epinephrine

and

isoproterenol

on

plasma

The effect of

corticosterone

levels

was

associated with a parallel and dose-related increase in plasma ACTH
(Berkenbosch et al., 1983).
Tilders et al. (1985) found that intravenous infusion of epinephrine

increased

plasma

ACTH

and

corticosterone

comparable to those induced by stress.

to

levels

that

are

The stimulation of ACTH secretion

by epinephrine appears to be mediated via CRF and P-adrenergic receptors
since it was prevented by i.p. injections of propranolol or administration
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of CRF antiserum.
In vitro studies with incubated rat hypothalami demonstrated that
norepinephrine produced a dose-dependent stimulation of CRF release which
was prevented by the
The

~-adrenoceptor

antagonists propranolol and timolol.

norepinephrine-induced CRF release was

not

affected by

the a 1 -

adrenoceptor antagonists thymoxamine, prazosin or corynanthine or the a 2 adrenoceptor antagonist idazoxan (Tsagarakis et al., 1988).

This study

suggests a stimulatory role for norepinephrine on CRF release that is
mediated

by~

receptors.

e. Role of Dopamine Neurons in Corticosterone Secretion
The PVN is uniformly innervated with dopaminergic neurons.

The

dopaminergic innervation of the PVN originates from cells of the arcuate
nucleus

(Al2),

zona

incerta

(Hokfelt et al., 1984).

(A13)

and periventricular nucleus

(Al4)

Immunocytochemical studies indicated that both

dopamine and norepinephrine terminals synapatically contact magnocellular
neurons on their dendrites or cell bodies (Decavel et al., 1987).

In

addition, tyrosine hydroxylase immunoreactivity has been reported in both
fibers and neurons of the PVN (Swanson et al., 1981; Liposits et al.,
1986).
Dopamine has been shown to stimulate corticosterone secretion.
Injection (i.p.) of the dopamine agonist pergolide caused a dose-dependent
increase in plasma corticosterone levels, which was blocked by pretreament
with the dopamine antagonists spiperone and haloperidol.

Spiperone also

partially inhibited the increase in plasma corticosterone levels following
administration of quipazine, a serotonin agonist, although much higher
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doses were required than for pergolide.

In addition,

the peripheral

dopamine antagonist domperidone did not prevent the increase in plasma
corticosterone levels by pergolide (Fuller and Snoddy,

1981).

These

results support a role for central dopamine receptors in corticosterone
secretion.

Similar results were obtained by Jezova et al (1985), who

found that subcutaneous injection of the dopamine agonist apomorphine
increased plasma ACTH and corticosterone levels.

Haloperidol pretreatment

completely inhibited the apomorphine-induced stimulation in plasma ACTH.

5. Role of 5-HT Neurons in Corticosterone Secretion
Many studies support the hypothesis that stimulation of serotonergic
receptors

leads

to

increased corticosterone

secretion

in unstressed

animals (Buckingham and Hodges, 1979; Fuller and Snoddy, 1980; Fuller,
1981; Jones et al., 1976; Van de Kar et al., 1982).

Gibbs and Vale (1983)

reported that administration of the 5-HT uptake inhibitor fluoxetine to
anesthetized rats caused increased release of CRF-41 into hypophyseal
portal blood.

Lorens and Van de Kar (1987) demonstrated that plasma

corticosterone levels were increased by the 5-HT agonist MK-212, the 5HT1A agonists ipsapirone and 8-hydroxy-2-(di-N-propylamino)tetralin (8-0HDPAT) , and the serotonin releaser fenfluramine.

The 5-HT2 antagonist

LY53857

and

did not

prevent

corticosterone secretion.

the

effect

of MK-212

fenfluramine

on

These data suggest a possible role for 5-HT 1A

receptors in the stimulation of corticosterone secretion.

This conclusion

was confirmed by Koenig et al. (1987) and Gilbert et al. (1988).
The dorsal and median raphe nuclei in the midbrain are known to be
the major sources of serotonergic pathways to the hypothalamus (Azmitia
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and Segal, 1978; Parent et al.,

1981; Van de Kar et al.,

1980).

In

particular, the median raphe nuclei are the primary source of 5-HT fibers
to the suprachiasmatic nucleus, anterior hypothalamic area and medial
preoptic area,

while the anterolateral hypothalamic area and arcuate

nucleus receive 5-HT inputs from both the dorsal and median raphe nuclei
(Van de Kar and Lorens, 1979).
With respect to the PVN, a relatively light serotonergic innervation has been described (Aghajanian et al.,

1973;

Steinbusch,

1981).

Immunocytochemical studies by Sawchenko et al. (1983) found that the major
source of ascending serotonergic projections to the PVN were from the
dorsal and median raphe nuclei and the medial lemniscus.

A significant

decrease in PVN serotonin was reported following surgical destruction of
the dorsal raphe nucleus (Palkovits et al., 1977).
Immunocytochemical

studies

by

Liposits

(1987)

demonstrated

a

moderate serotonergic innervation to the PVN, with a prominent distribution to the parvocellular subnuclei.
overlap with CRF-immunoreactive axons.

Serotonergic axons were found to
Further ultrastructural examina-

tion revealed that serotonin-containing terminals formed axo-dendritic and
axo-somatic synapses with CRF-immunoreactive neurons.
that

serotonin

can

influence

CRF-containing

This study suggests

neurons

via

synaptic

transmission.
Midline injections of 5,7-dihydroxytryptamine (5,7-DHT) into the
raphe nuclei produced significant depletions of 5-HT in the hypothalamus,
and prevented the increase in corticosterone following stimulation of
cortical and limbic areas

(dorsal hippocampus,

basolateral amygdala,

mesencephalic reticular formation and medial septal nucleus).

The ether-
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induced increase in corticosterone levels was not affected by this lesion.
Injection of 5, 7-DHT into the PVN also prevented the adrenocortical
response to dorsal hippocampal and photic stimulation.

These results

suggest that 5-HT in the PVN mediates the stimulation of corticosterone
secretion following either peripheral or central stimuli (Feldman et al.,
1987).
In contrast, Van de Kar et al. (1982) demonstrated that the PCAinduced stimulation of corticosterone secretion was not mediated by either
the dorsal or median raphe nucleus.

In addition, posterolateral cuts

which interrupted caudal inputs to the hypothalamus did not block the
serotonergic stimulation of corticosterone secretion by the serotoninreleasing drug PCA (Van de Kar et al., 1985).
Serotonin has been shown to play a role in mediating the diurnal
variation in basal plasma corticosterone in rats.

Plasma corticosterone

levels peak at the onset of the dark cycle in the rat (Krieger and Hauser,
1978; Wilkinson et al.,
chlorophenylalanine
evening

increase

Depletion of brain serotonin with p-

1979).

(PCPA)

raised the morning low and prevented the

in plasma corticosterone

Vernikos-Danellis et al., 1973).

(Scapagnini et al.,

1971;

Similar results were observed with rats

fed a tryptophan-free diet for 21 days (Vernikos-Danellis et al., 1977).
In humans, plasma cortisol and ACTH levels also follow a diurnal rhythm,
except that the highest levels are found in the morning (0600h), with the
lowest values

at night

(2200h)

(Watabe et al.,

This

1987).

study

demonstrated a similar diurnal pattern for plasma CRF, with peak values
at 0600h and significantly lower levels at 1800h and 2200h.
suggest

that

the

diurnal

rhythm

in

CRF

These results

secretion plays

a

role

in
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regulating the diurnal rhythm in cortisol and ACTH secretion.
In conclusion, the studies presented in this section demonstrate the
presence of CRF cell bodies in the PVN, and a role for brain catecholamines in the stimulation of CRF secretion.

C. STRESS
1. Introduction
a. Definition
Stress has been defined by Hans Selye (1973) as the "non-specific
response of the organism to any demand made upon it" (Selye, 1973).

By

this definition, the word "stress" describes a response, but it is often
used interchangeably with the stimulus or "stressor" that elicits the
response (Mills, 1985).
variety of stimuli.

The stress response can occur following a wide
Stressors

environmental or psychological.

can be classified as

physiological,

Physiological stressors include surgery,

injection of foreign substances such as proteins, diseases, anesthesia,
loss of blood,

exercise and trauma.

Environmental stressors include

prolonged exposure to cold or heat, noise,
chemicals.

Psychological

stressors

radiation, pollutants and

include

a

threatening predator,

intense competition among members of the same species, prolonged conflict,
learning how to avoid a painful stimulus

(such as

electric shock),

conditions characterized by novelty, anticipation, fear, unpredictability
and change (Kidman, 1984; Gray, 1971; Mills, 1985).

b. Cannon's Alarm Reaction
Cannon (1914) described the role of the sympathetic nervous system
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in the "fight or flight" emergency or "alarm reaction".

This reaction

permits the body to perform more strenuous muscle activity than normally
possible.

Cannon noted that when animals underwent stressful situations

there was a marked increase in the activity of sympathetic nerves.

This

stimulation of the autonomic nervous system mobilizes the body's resources
to deal with the stressful situation.

The alarm reaction is thought to

be transmitted from the hypothalamus through the reticular formation to
the spinal cord to evoke massive catecholamine release from the sympathetic nerve endings (Guyton, 1981).

c. Selye's General Adaptation Syndrome
Selye (1936) was the first to describe a biological stress syndrome
produced by diverse noxious agents.

His description subsequently became

known as the "general adaptation syndrome", a three-stage process that
describes the long-term adjustments elicited by prolonged stress.

The

first stage is the "alarm reaction", when the body is exposed to diverse
stimuli
reaction,

to which
a

it has

not adapted.

"stage of resistance" occurs

Following

the

initial alarm

in which resistance to the

original stressor (which continues to exist) is increased, but resistance
to other stressors is decreased.
enough time,

If the stressor continues for a long

the stage of resistance develops into a final "stage of

exhaustion", with a catastrophic decline in resistance to all other types
of stressors. If the stress reaction continues undiminished, death ensues
(Selye, 1976).
In cases of prolonged stress, Selye (1946) described a major role
for glucocorticoids during the alarm reaction.

Glucocorticoids increase
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sugar deposition in the liver and facilitate the conversion of proteins
and fats

into sugars.

They enhance the responsiveness of the blood

vessels to epinephrine and norepinephrine.
with energy sources

to be

This will provide the body

rapidly utilized

in the

event of sudden

strenuous activity.

Glucocorticoids also lower the body's resistance to

infection and have

anti-inflammatory properties,

numbers

of lymphocytes

and eosinophils,

inhibition of antibody formation.

including decreased

decreased thymus weight and

Stress appears to play a major role as

a suppressor of immune function.
Other physiological changes induced by prolonged stress include a
depression of thyroid activity, inhibition of body growth, and suppression
of sexual and reproductive behavior (Gray, 1971).

In simple terms, the

body copes with prolonged stress by closing down any process that detracts
from immediate energy mobilization.

d. Sympathetic and Endocrine Stress Responses
The biological stress response is believed to be mediated by the
stimulation of two systems (Kidman, 1984).

One, the pituitary-adrenal

axis, is activated by sensory nerves which relay information regarding
external stressors to the hypothalamus.

Hypothalamic neurons contain CRF

and release it into the portal circulation,

stimulating the anterior

pituitary gland to produce and release ACTH.

In response, the adrenal

cortex produces corticosteroids.
bloodstream

inhibit

the

The glucocorticoids liberated into the

synthesis

and/or

release

of ACTH

from

the

pituitary by a negative feedback mechanism.
The second system is the sympathetic adrenal medullary axis, which
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plays an important role in the alarm reaction described by Cannon.

In

this system, once the sensory nerves relay the information regarding the
external stressors to the hypothalamus, it relays a message through the
reticular formation to the spinal cord to evoke massive catecholamine
release from the sympathetic nerve endings and adrenal medulla.

e. Physiological Changes in Response to Stress
Selye

(1950)

emphasized the

fact

that

the physiological changes

(primarily in the adrenal cortex) in response to stressful stimuli were
the same irrespective of the stimulus used.
the

stressor

biological

is

physiological,

stress

response

This suggests that whether

environmental

would always

be

or

the

psychological,
same.

This

the

general

hypothesis allows for comparison of physiological responses following a
variety of different stressors.
Since

stress

is

abstractly

defined,

it

is

helpful

to

have

quantifiable parameters that are known to change when animals or humans
are

exposed

to

a

stressor.

In

the

experiments

presented

in

this

dissertation, the neuroendocrine responses to stress were measured with
respect to plasma renin activity and plasma corticosterone levels.
stressor

was

a

behavioral

paradigm

known

as

conditioned

fear,

The
or

conditioned emotional response (CER), designed to produce psychological
stress.

B. The Conditioned Fear Paradigm
a. Description
Each rat was transported from his home cage to the stress chamber.

39

Ten

minutes

following

placement

in

the

chamber,

the

experimental

(stressed) rat received an inescapable foot shock and was returned to his
home cage.

This procedure was repeated for three consecutive days.

In

previous experiments it was apparent that the stressed rats had learned
that their placement in the chamber will be followed by a foot shock.
the third day,

in contrast to the control animals,

By

the stressed rats

defecated, urinated and demonstrated freezing (no movement) behavior.

On

the fourth day, after 10 minutes in the test chamber, instead of receiving
shock the rat was removed, transported to a third area outside the stress
room and immediately sacrificed by decapitation.

The control rats were

treated identically except that shock was not administered at any time.
A more detailed description of this procedure can be found in the Methods
section.

b. Pavlov's Dog: Classical Conditioning
Ivan Pavlov (1927) presented studies on classical conditioning in
which a dog was repeatedly exposed to a situation where an initially
neutral stimulus (e.g., a tone or light flash) was followed directly by
a stimulus of biological significance to the animal (food).
"unconditioned
responses"

stimulus"

(UCR) .

As

(UCS)

elicited

the pairings

a

range

of stimuli

of

were

The latter

"unconditioned
continued,

the

originally neutral stimulus became a "conditioned stimulus" (CS), capable
of eliciting some part of the responses formerly elicited exclusively by
the UCS.
tion.

This "conditioned response" (CR) in Pavlov's dogs was saliva-
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c. Definition of Fear
Fear can be defined as
stimulus.

an emotional response

to an aversive

In this respect, it is classified as an emotion.

element that emotions share is

that they represent a

"reinforcing event" or signals of reinforcing events.
include both rewards and punishments.

The common

reaction to a

Reinforcing events

An example of a punishment would

be the removal of a reward, or the failure of an expected reward to occur.
The emotional responses will depend on the type of reinforcing event and
the animal's knowledge of these events (Gray, 1971).

d. Measures of Fear
Hall (1941) established the link between the study of fearfulness
and the use of defecation as a measure of fear.

He developed a standard

test (the Open Field) for the measurement of emotional defecation.

Parker

(1939) demonstrated that defecation occured in response to a variety of
situations which one would expect to elicit fear. He recorded the amount
of defecation elicited by six different situations:

the Open Field test,

a buzzer, sudden dropping, a tilting box that caused the rat to slide down
an inclined plane,

immobilization and forced swimming.

High positive

correlations were obtained between the scores on every test.

Further

factor analysis indicated a general factor (presumably fear) which all the
tests were measuring.

These results support the statement by Selye (1950)

that physiological changes in response to stressful stimuli are the same
irrespective of the alarming stimulus used.

41

e. Emotional Factors
There

are

physiological

events

that

occur within

influence its behavior in a given environment.

an

animal

to

In 1890, William James

and Carl Lange independently expressed a theory for the interrelationship
between physiological events and emotional responses.
theory,

as

it

is

known,

physiological changes

defines

emotions

as

the

that occurred in response

The James-Lange

perception of

to a

stimulus.

the
For

example, the feeling of being frightened would consist solely of feeling
your heart pound, your breathing become faster, and so on.

Unfortunately,

it

functions

is

not

possible

to

isolate

specific

physiological

correlate them exclusively with a particular emotional state.
the role of emotional factors should not be overlooked.

and

However,

Studies by Mason

et al. (1976) recognize the sensitivity of the pituitary-adrenal cortical
system to psychological influences.

Departing from Selye's non-specific

physiological response hypothesis (1950), Mason et al.
that

there

stimuli.

are

similar

psychological

reactions

to

(1976) proposed
various

external

Factors such as heat, cold, fasting or exercise do not produce

an adrenal cortical response if emotional arousal is carefully avoided
(Mason et al.,

1976).

To illustrate, on the first day of starvation,

food-deprived monkeys that could watch other monkeys being fed in nearby
cages had an elevation of blood corticosteroids that occurred too early
to be attributed to a physiological response due to a

lack of food.

However when the monkeys were carefully adapted to their surroundings,
kept in a

soundproof room,

and maintained on regular "feeding"

(non-

caloric, fruit-flavored pellets) schedules, there were none of the usual
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changes in glucocorticosteroids associated with fasting periods.

Mason

concluded that there is a considerable degree of emotional disturbance,
due to discomfort,

inherent in the laboratory setting.

Kidman (1984)

expanded this idea to a "cognitive theory of stress" which says that, in
spite of our best efforts

to control hunger,

temperature and other

environmental pressures, we still become frustrated over perceived threats
to our welfare and security.

Thus, the stress response consists of a

variety of physiological and psychological factors.

These factors are

most likely integrated through the central nervous system, in particular
the hypothalamus, as it coordinates the interaction between the autonomic
nervous system, the endocrine system and many forms of emotional behavior.

3. Cardiovascular Changes in Response to Classical Conditioning
Stressful conditions have been implicated in the

etiology of

cardiovascular disease and hypertension (Hollenberg et al., 1981; Manuck
et al., 1981; Schulte et al., 1984).

Changes in heart rate and arterial

blood pressure can be classically conditioned (Dykman and Gantt, 1956).
A neutral stimulus that elicits no cardiovascular response (conditioned
stimulus) is paired with another stimulus (unconditioned stimulus) that
evokes a vigorous cardiovascular response (unconditioned response).

After

several pairings of the conditioned and unconditioned stimulus,

the

previously neutral conditioned stimulus will eventually cause cardiovascular changes in anticipation of the unconditioned stimulus (Cohen and
Randall, 1984).
Smith et al. (1984) have demonstrated that the perifornical area of
the hypothalamus (referred to as HAGER, the Hypothalamic Area Controlling
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Emotional Responses) is responsible for the cardiovascular responses that
accompany emotional behavior in monkeys.
emotion

included

cardiovascular

Their operational definition of

responses

(elevated

arterial

pressure) and a behavioral response (suppression of lever pressing).

blood
'When

the hypothalamic area (HAGER) was electrically stimulated, it produced the
same

cardiovascular

situation.

pattern

as

that

associated

with

the

emotional

The cardiovascular but not the behavioral portion of the

emotional response was lost following ablation of the HAGER.

Afferents

to the HAGER include the amygdala and septal area as well as brain stem
autonomic areas such as the central grey, nucleus tractus solitarius, and
dorsal motor nucleus of the vagus.

Efferents include a direct projection

to the intermediolateral cell column cells of the thoracic cord,

an

important site with respect to sympathetic control of cardiovascular
function.

Other efferent projection sites include the raphe nuclei, the

parabrachial complex, the hypothalamic PVN and the periaqueductal grey.
Cardiovascular changes have been observed with the Sidman avoidance
behavioral testing (Galosy et al., 1982).
(Sidman,

1953)

The Sidman avoidance paradigm

is used frequently to evaluate cardiovascular changes

associated with the postponement of electric shock contingent upon an
appropriate reponse.

The paradigm involves delivery of electric shock at

regular intervals unless a response (such as lever pressing) occurs to
delay the shock.

If the animal presses the lever at least once during the

interval, it can avoid all shocks (Turkkan et al., 1982).
Anderson and Brady (1971, 1972) observed decreased heart rate and
increased pulse and arterial blood pressure during the anticipatory preavoidance period.

Once the avoidance test was underway, the heart rate
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rapidly increased above pre-avoidance levels while pulse and arterial
blood

pressure

remained

elevated.

Further

pharmacological

studies

indicated that the ~-adrenoceptor blocker propranolol partially attenuated
the

heart

rate

elevations

during

avoidance,

but

did not

affect

the

increases in blood pressure in either avoidance or pre-avoidance periods
(Anderson

and

Brady,

phenoxybenzamine

1976).

blocked

the

In

similar

elevation

studies,

the

a-antagonist

in blood pressure

during

the

avoidance period but did not affect pre-avoidance changes in heart rate
and arterial blood pressure (Anderson et al., 1976).

From these and other

studies, Galosy et al. (1982) suggested that reduced heart rate during the
pre-avoidance period is dominated by parasympathetic mechanisms, whereas
the arterial blood pressure levels may be mediated by peripheral vascular
mechanisms which do not involve
mediated shifts

in blood flow

avoidance period,

a

receptors,

(Anderson et

perhaps cholinergicallyal.,

1976).

During the

a combination of increased sympathetic and decreased

parasympathetic activity leads to increased heart rates, while elevated
arterial pressure is due to continued sympathetic peripheral vasoconstriction (Galosy et al., 1982).
In
arithmetic

humans,
test

the
(Brod

stress
et

response,

al.,

1959),

as

elicited

consisted

of

by
the

a

demanding
following:

vasodilatation in skeletal muscle, coronary vessels and brain, while most
other resistance vessels and veins underwent a neurogenic vasoconstriction.

Increased sympathetic and decreased parasympathetic influences on

the heart resulted in tachycardia, increased cardiac ouput and slightly
increased mean arterial
increased

epinephrine,

pressure.
ACTH,

Neuroendocrine

corticosteroids,

responses

vasopressin

included

and

renin-
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angiotensin-aldosterone by means of sympathetic nerve stimulation of the
kidney (Brod, 1970).

Brod et al.

(1962) demonstrated that this cir-

culatory pattern exists in hypertension, especially the early stages.
Eliasson (1984) observed that the limbic-hypothalamic pattern of stress
responses is nearly identical in animals and man.

He proposed that modern

humans develop hypertension because they are socially deprived of the
acting-out behavior which is a large part of the stress or defense
reaction.

However, the autonomic and hormonal changes associated with

the stress reaction are not suppressible, therefore hypertension results.

4. Neuroendocrine Changes in Response to Stress
a. Stress-Induced Renin Secretion
The

physiological

response

to

stress

involves

the

release

of

catecholamines from the adrenal medulla and sympathetic nerve endings.
Stimulation of the renal nerves increases renin secretion (Di Bona, 1985;
Blair et al., 1985), and this stimulatory effect is mediated, at least in
part, via norepinephrine released at the endings of the postganglionic
sympathetic neurons that innervate the kidneys (Davis and Freeman, 1976;
Reid et al, 1978; Ganong and Barbieri, 1982).

Circulating epinephrine and

norepinephrine can also stimulate renin secretion.
Many investigators have reported increases in plasma renin activity
in response to a variety of stressors.

Clamage et al.

(1976) reported

increases in plasma renin activity in rats following 30 minutes exposure
to either novel "open field" environment or the presence of a hungry cat.
Jindra et al.

(1980) observed increases in plasma renin activity after

acute and repeated immobilization stress.

Paris et al. (1987) reported
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increased plasma renin activity by the following stressors:
conditioned fear paradigm; 20 minute immobilization;

12 minute

20 minute forced

swimming in cold water; 2, 12 and 22 minutes of intermittent footshock;
and a 3 minute conditioned fear paradigm with 0, 10, 30 and 60 minute
Blair et al.

recovery.

(1976) reported an elevation of plasma renin

activity in baboons during avoidance performance.

Gotoh et al.

(1985)

demonstrated that bilateral knife cuts behind the hypothalamic paraventricular nucleus (PVN) reduced the renin response to immobilization and
the gravitational stress of head-up tilting.

Plasma renin activity

clearly can be increased by many different types of stressors.
Sigg et al. (1978) found that restraint causes an increase in plasma
renin activity which was not blocked by pretreatment with the &-adrenergic
antagonists dl-propranolol or sotalol.

However, propranolol pretreatment

prevented the increase in plasma renin activity following swim stress and
ether stress (Pettinger et al., 1972) and intermittent footshock (Leenen
and Shapiro, 1974).

Also, Van de Kar et al.

(1985) have shown that

propranolol significantly inhibits the increase in plasma renin activity
following a three-minute conditioned fear paradigm.

Evidence for a role

of central catecholamines in stress-induced renin secretion was provided
by Lightman et al.

(1984)

who

demonstrated

that

injections

of

the

catecholamine neurotoxin 6-0HDA into the dorsal noradrenergic bundle
markedly attenuated the increase in plasma renin activity in response to
hemorrhage.

Kobayashi et al. (1975) have reported that afferent fibers

from the locus coeruleus to the PVN travel in the dorsal noradrenergic
bundle.

These studies suggest that central catecholaminergic projections

to the PVN may be involved in the renin response to stress.
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b. Stress-Induced Corticosterone Secretion
1. Introduction
Corticosterone levels have been shown to increase in response to
several stressors.

For example, Armario et al. (1986) demonstrated that

the corticosterone response to stress is directly related to the intensity
of the stress stimulus.

The stressors used in their study were graded

levels of low intensity stressors (either transfer to a novel cage or
room, or a loud noise).
Kant

et

al.

(1983),

These results are in agreement with findings by

who

demonstrated

that

increases

in plasma

ticosterone levels were related to the intensity of footshock.

cor-

They found

that corticosterone secretion was very sensitive not only to an obvious
stressor (footshock) but also to any change in the environment accompanying the procedure.

Simply placing the rat in the shock box without

delivery of any current elicited a strong corticosterone response.

These

studies suggest that the increase in corticosterone levels in response to
stress can represent a

sensitive index of the

intensity of emotional

arousal experienced by the animals.
Dohanics et al.

(1986)

found that the adrenocortical response to

ether stress occurs independently of neurohypophyseal function, and that
the

full

corticosterone

and

ACTH

response

to

ether

or

ether

plus

laparotomy stress requires not only an intact PVN but also an intact
neurointermediate lobe.

2. Stress-Induced Secretion of CRF
CRF has been shown to mediate stress-induced ACTH release in rats

48
(Rivier and Vale,

1983).

CRF also has been shown to initiate other

biological actions in response to stress.

For example, injections of CRF

into the cerebral ventricles produced significant increases in plasma
concentrations

of epinephrine,

norepinephrine,

glucagon and glucose,

elevated mean arterial pressure and heart rate, and inhibited gastric acid
secretion.

Pretreatment with the ganglionic blocking drug chlorisondamine

completely abolished the increases in plasma catecholamines and glucose,
heart rate and blood pressure (Lenz et al., 1987).
activate brain catecholamine systems.

CRF has been shown to

Studies by Dunn and Berridge (1987)

demonstrated that injections of CRF into the cerebral ventricles of mice
resulted in increased dihydroxyphenylacetic acid (DOPAC):dopamine ratios
in prefrontal cortex, septum, hypothalamus and brain stem compared to
saline controls.

The ratio of 3-methoxy-4-hydroxyphenylethyleneglycol

(MHPG):norepinephrine
hypothalamus.

was

increased

in

the

prefrontal

cortex

and

DOPAC and MHPG are the major catabolites of dopamine and

norepinephrine, respectively.

CRF release has been measured in conscious,

unrestrained rats using a push-pull cannula system implanted in the median
eminence (Ixart et al., 1987).

Basal CRF release occurs in a pulsatile

pattern with peaks about every 45 minutes (peak mean 9.0 ± 0.7 pg vs.
trough 4.1 ± 0.3 pg).

Ether elicited an increase in CRF which lasted

about 45 minutes with peak values of 54.3 ± 3.2 pg.

3. Stress-Induced Secretion of ACTH
Gibbs (1984) found that ACTH secretion increased in response to
restraint, cold or ether stress.

However, Armario et al.

(1985) have

found dissociations between ACTH and corticosterone responses:

the ACTH
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response to restraint stress, unlike the corticosterone response, was the
same in control and in chronically stressed rats.

This suggests that the

increased corticosterone levels from restraint stress are not necessarily
due only to increased pituitary ACTH release.
The increase in ACTH following hemorrhage was prevented by PVN
lesions, while the responses of renin, epinephrine, norepinephrine, mean
arterial blood pressure and heart rate to hemorrhage were not affected
(Darlington et al., 1988).

However, these lesions consisted of creating

an island of the PVN and dorsal hypothalamus by lowering a triangular
(Halasz-type) knife into the third ventricle to the level of the PVN and
then rotating.

This may have disrupted fiber pathways to and from the

PVN without actual damage to PVN cell bodies.
Makara et al. (1986) proposed that ACTH hypersecretion following
adrenalectomy is driven primarily by CRF- and/or vasopressin-producing
neurons in and around the PVN, while either (a) other sources of CRF-41,
(b) increased pituitary sensitivity, or (c) other hypothalamic factors
may restore the stress-induced ACTH release in the absence of the PVN.
The effect of bilateral lesions of the PVN on circadian rhythm and
ether stress responsiveness of plasma ACTH and corticosterone were studied
in chronically cannulated female Sprague-Dawley rats.

Three weeks after

PVN lesions, ACTH values had dropped by at least half, and the diurnal
maximum and amplitude for corticosterone were diminished by one third.
The peaks for both hormones following ether stress were only half as high
as the control peaks (Ixart et al., 1982).
of the PVN as
secretion.

These results support the role

a mediator of stress- induced ACTH and corticosterone
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4. Role of Vasopressin in Stress-Induced Corticosterone Secretion
Vasopressin promotes
maintain plasma volume.
One

hypothalamus.

the retention of water by the kidney,

to

There are two major vasopressin systems in the

system has cell bodies

in the PVN and supraoptic

nuclei, projecting through the internal zone of the median eminence to
the pars neuralis of the pituitary gland.
cell bodies

in the

PVN with nerve

(Silverman and Zimmerman, 1983).

The other system consists of

terminals

in the median eminence

One difference between these systems is

that adrenalectomy resulted in increased staining intensity of vasopressin
immunoreactive nerve fibers in the external zone of the median eminence,
whereas the

fibers

of the neural lobe or intenal zone of the median

eminence were not affected (Zimmerman et al., 1977).
Vasopressin has been shown by Tilders et al.

(1985)

to have an

important role in the stress-induced activation of the pituitary-adrenal
system, possibly by potentiating the effects of CRF.

Pretreatment of rats

with an antiserum to vasopressin inhibited the ACTH response to both
restraint
potentiate

and
the

formalin

stress.

activity of CRF

Vasopressin has
(Gillies

secretion is stimulated by hemorrhage

et al.,

(Robertson,

also

been

1982).
1977),

shown

to

Vasopressin
hypoglycemia

(Bayliss and Robertson, 1980), electric shock (Husain et al., 1979) and
ether (Gibbs, 1984).
Further evidence for the involvement of vasopressin in the ACTH
response to stress is that the vasopressin antagonist dpTyr(Me)arginine
vasopressin decreases ether stress-induced ACTH release, and administration of both the vasopressin antagonist and CRF antiserum completely
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prevented stress-induced ACTH secretion (Rivier and Vale, 1983).

However,

some studies reported that dpTyr(Me)arginine vasopressin does not block
either the intrinsic ACTH-releasing activity or its synergistic effects
with CRF (Baertschi et al., 1984; Knepel et al., 1984) and, therefore,
should be avoided in studies involving ACTH release (Tilders et al.,
1985).

5. Role of Catecholamines in Stress-Induced Corticosterone
Secretion
Controversy still exists as to whether catecholamines play an
excitatory or inhibitory role in stress-induced corticosterone secretion.
i. Evidence for an Inhibitory Role of Catecholamines
Brain norepinephrine has been postulated to inhibit ACTH secretion
(van Loon et al.,

1971; Weiner and Ganong,

1978).

Eisenberg (1975)

administered reserpine (systemically) or phenoxybenzamine (centrally) and
found an augmentation of the plasma corticosterone response to ether.
This suggests that norepinephrine may function in the central nervous
system to inhibit the stress response.

However,

reserpine is not a

selective noradrenergic depletor as it will also deplete serotonin stores
(Bugnon et al., 1983).

Suemaru et al. (1985) observed significant increases in serum ACTH
and corticosteorne levels 15 minutes after the onset of either etherlaparotomy or cold-restraint stress.

The hypothalamic CRF concentration

showed a rapid increase 2.5 minutes following ether-laparotomy stress,
followed by a significant decrease after 15 minutes, and a subsequent
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increase.

Norepinephrine concentration in the hypothalamus was reduced,

whereas dopamine concentration was increased.

Epinephrine concentrations

did not show a significant change throughout the stress procedure.

From

these observations they concluded that norepinephrine in the hypothalamus
may not be involved in stimulating hypothalamic CRF secretion in the early
phase of acute stress.
Glavin et al.

(1985) depleted brain norepinephrine in rats by

injecting the dopamine-E.-hydroxylase inhibitor FI.A-63

(to prevent the

conversion

by

of

reserpine-like
serotonin.

dopamine

to

vesicular

norepinephrine)

depletor

of

followed

norepinephrine,

R04-1284,
dopamine

a
and

This treatment produced significant depletion of norepineph-

rine in all brain regions examined.

Norepinephrine depletion did not

prevent the increase in plasma corticosterone levels following coldrestraint stress.
significant

However,

difference

in

in the non- stressed rats,
plasma

corticosterone

norepinephrine-depleted and saline-treated rats.

there was no

levels

between

the

The authors suggest that

norepinephrine does not mediate cold restraint stress-induced increases
in plasma corticosterone levels, nor does it play an inhibitory role with
respect to corticosterone secretion.
non-related

stimuli

(cold vs.

However, this study combines two

immobilization)

as

stressors

without

addressing how this could affect hormonal responses.
Reinstein et al. (1985) have demonstrated that acute, uncontrollable stress (restraint and intermittent footshock for one hour) depleted
norepinephrine
Pretreatment

in the rat brain
with

supplemental

(increased norepinephrine turnover).
tyrosine

(to

prevent

norepinephrine

depletion) prevented hypothalamic norepinephrine depletion and suppressed
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the increase in plasma corticosterone, suggesting an inhibitory role for
norepinephrine.

However,

these corticosterone data were reported as

percent of non-stressed control values,
ug/dl).

which were quite high

(37 .4

In conclusion, there is weak evidence in these studies to support

an inhibitory role for norepinephrine in corticosterone secretion.

ii. Evidence for a Stimulatory Role of Catecholamines
in Stress-Induced Gorticosterone Secretion
Gibson et al. (1986) found that bilateral injections of 6-0HDA into
the

PVN

prevented

the

restraint

stress-induced

increase

in

plasma

Pretreatment with the a 1 -adrenoceptor antagonist

corticosterone levels.
prazosin,

at a dose which did not influence resting hormone levels,

inhibited

the

stress.

increase

in plasma corticosterone

following

restraint

The authors suggest an excitatory role for norepinephrine via a

receptors in CRF release during acute stress.

Similarly, Feldman et al.

(1986) injected 6-0HDA into the PVN and found that PVN norepinephrine
depletion did not affect basal levels or ether stress-induced increases
in corticosterone levels, but it did significantly

inhibit the adrenal

response to photic and acoustic stimuli and sciatic nerve stimulation,
suggesting that noradrenergic terminals in the PVN play a role in the
activation of adrenocortical responses following afferent neural stimuli.
Smythe et al. (1983) support the hypothesis that stress-induced ACTH
release from the pituitary is stimulated by hypothalamic noradrenergic
neuronal

pathways.

They

measured

norepinephrine

activity

in

the

mediobasal hypothalamus by assessing the ratio of 3,4-dihydroxyphenylethyleneglycol

(DHPG) /norepinephrine.

Hypothalamic

norepinephrine
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activity was rapidly increased by cold swim stress in the rat, accompanied
by increased ACTH/corticosterone release into the blood.

Norepinephrine

activity and ACTH release were also stimulated in rats following ether
stress.

The significant correlation between serum corticosterone and the

ratio of hypothalamic DHPG/norepinephrine (shown by linear regression
analysis of the combined data for control and stressed rats in their
studies) is not evidence, but suggests that hypothalamic norepinephrine
neuronal activity may play an important stimulatory role in stress-induced
ACTH release.
Studies by Johnston et al.
Smythe et al. (1983).

(1985) support the data presented by

Norepinephrine, dopamine and 5-HT concentrations

as well as the concentrations of their respective metabolites MHPG, DOPAC
and 5-hydroxyindole-3-acetic acid (5-HIAA) were measured by HPLC.

The

metabolism of norepinephrine, dopamine and 5-HT in different rat brain
nuclei was estimated by the ratio of the metabolite to its respective
amine.

Ether stress produced large increases in plasma ACTH, accompanied

by significant increases in norepinephrine metabolism in the PVN, arcuate
and dorsomedial nuclei.

Serotonin metabolism was decreased in the PVN,

supraoptic nucleus and caudal division of the arcuate nucleus,

while

significant increases in 5-HT metabolism were detected in the suprachiasmatic nucleus and rostral division of the arcuate nucleus.
metabolism was
arcuate

Dopamine

selectively increased in the rostral division of the

nucleus.

The

authors

interpret

the

data

as

suggesting

a

stimulatory role for norepinephrine, possibly in the PVN with respect to
ACTH secretion.
Studies by Mermet and Gonon (1988) used differential normal-pulse
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voltammetry combined with carbon fiber electrodes to measure in vivo
extracellular catechols released by noradrenergic nerve terminals in the
PVN.

In rats pretreated with the monoamine oxidase inhibitor pargyline,

ether stress produced an increase in the catechol signal corresponding to
extracellular norepinephrine.

Electrical stimulation of the ventral

noradrenergic bundle also caused an immediate increase in the signal.
The

increase

in

norepinephrine

release

following

ether

immediate and lasted as long as the stimulus duration.

stress

was

No dopamine

release was recorded from either the striatum or the Al3 dopaminergic cell
body group caudal to the PVN.

These data suggest a facilitatory action

of norepinephrine on PVN cell bodies which are involved in the hormonal
responses to stress.
Immobilization stress (varying from 15 to 180 minutes) significantly increased MHPG-S04 levels and decreased norepinephrine levels in the
following

rat

brain

regions:

hypothalamus,

amygdala,

hippocampus,

thalamus, pons, medulla and cerebral cortex, with the most rapid and
profound increase in MHPG-S0 4 found in the hypothalamus.

However, the

basal ganglia demonstrated the reverse process- increases in norepinephrine levels with transient decreases in MHPG-S04 levels.

There was a

concomitant increase in plasma corticosterone levels following immobilization stress (Tanaka et al., 1982).

This study suggests that norepineph-

rine released in the hypothalamus during immobilization stress may play
a role in the stress-induced increase in corticosterone levels.
Beaulieu et al. (1987) demonstrated that bilateral lesions of the
central nucleus of the amygdala significantly inhibited the stress-induced
ACTH secretion following immobilization.

These lesions also reduced the
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stress-induced

noradrenergic

activity

in

the

anterior

and

lateral

hypothalamic areas, the PVN and arcuate nucleus, and the bed nucleus of
the stria terminalis.

These results suggest that norepinephrine plays a

stimulatory role in ACTH secretion and is somehow regulated by neurons in
the central nucleus of the amygdala.
As stated earlier,
thought

to be

the

source

the ventral noradrenergic bundle (VNAB)
for

is

the noradrenergic

modulation of ACTH

secretion (see CORTICOSTERONE: Role of the VNAB).

Szafarczyk et al.

(1985) have shown that injection of 6-0HDA into the VNAB obliterates the
circadian patterns for ACTH and corticosterone secretion, and also caused
an 80% inhibition of the ACTH response to stress.
Injections of 6-0HDA into the VNAB also prevented the increase in
corticosterone secretion following exposure to photic and acoustic stimuli
and sciatic nerve stimulation (Feldman et al., 1988).

However, basal

levels of corticosterone and ether-induced increases in corticosterone
were not affected.

The 6-0HDA-injected rats had average norepinephrine

depletions of 72% in the mediobasal hypothalamus and 78% in the paraventricular nucleus when compared to vehicle-injected rats.

These data

support previous studies (Feldman et al., 1986) in which 6-0HDA injections
into the PVN did not affect basal levels or ether-induced increases in
corticosterone levels, but did significantly inhibit the adrenal response
to photic and acoustic stimulation and sciatic nerve stimulation.

These

studies suggest that norepinephrine plays a role in the activation of
adrenocortical responses following afferent neural stimuli.
In contrast, Velley et al. (1988) have shown that 6-0HDA lesions
in the locus coeruleus did not prevent the effect of novel environment
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stress on corticosterone, although there was a significant (53%) depletion
of hypothalamic norepinephrine. However, this can be explained by the fact
that about 90% of the norepinephrine supply to the PVN originates from the
lower brainstem Al

and A2

cell

groups,

while

the

locus

coeruleus

projection to the PVN is only about 8% (Sawchenko and Swanson, 1982).

iii. Role of Epinephrine in Stress-Induced
Corticosterone Secretion
Szafarczyk et al.
epinephrine

(and

(1987)

demonstrated a

norepinephrine)

on

stimulatory role

corticosterone

release

for
when

intracerebroventricular (icv) injections of epinephrine or norepinephrine
induced ACTH release comparable to that occurring under conditions of
ether stress.

Epinephrine was more efficacious than norepinephrine on an

equimolar basis.

The stimulating effect of norepinephrine was reversed

by icv pretreatment with prazosin, an a 1 - adrenoceptor antagonist, whereas
the effect of epinephrine was inhibited by either prazosin or the .&blocker propranolol.

These results suggest that norepinephrine triggers

ACTH release via a 1 -adrenoceptors, whereas epinephrine acts via both a 1 and B-adrenoceptors.

It should be noted that they also administered a

combined pretreatment of prazosin and propranolol,

and this combined

treatment was no more effective than either antagonist alone.

They also

demonstrated that a unilateral juxta-PVN injection of either epinephrine
or norepinephrine produced an increase in plasma ACTH concentration with
a time course similar to that for an icv injection, and pretreatment with
anti-rCRF-41 serum caused a 50-60% reduction in the ACTH response to
either catecholamine.

Since the majority of diencephalic CRF neurons are
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located in the parvocellular subnuclei of the PVN (Swanson et al., 1983;
Liposits et al., 1985), these data suggest a role for a 1 and B receptors
in the PVN in the regulation of corticosterone secretion.
Additional evidence was obtained by Spinedi et al.
demonstrated

that

norepinephrine

to

central

inhibition

epinephrine,

of

the

enzyme

(1988) who

that

converts

phenylethanolamine-N-methyltransferase

(PNMT), produced a selective decrease in hypothalamic epinephrine levels,
significantly decreased the plasma ACTH response to ether stress, and at
later times also caused a selective decrease in CRF content.

In addition,

the altered ACTH response to ether stress was not due to changes in
arginine vasopressin levels or changes in pituitary responses to CRF.
These results support a stimulatory role of central epinephrine neurons
on CRF release.

6. Role of Serotonin (5-HT) in Stress-Induced
Corticosterone Secretion
The role of serotonin as a mediator of stress-induced corticosterone
secretion is not clear.

Electrolytic lesions in the dorsal raphe nucleus

prevented the stress-induced increase in corticosterone levels as well as
increases

in

plasma

renin

activity

and

plasma

renin

concentration

following a ten-minute conditioned fear paradigm (Richardson Morton et
al., 1986).

Other studies from our laboratory have shown that injection

of the neurotoxin 5,7-dihydroxytryptamine into the dorsal and median raphe
nucleus

did

not

corticosterone

prevent

secretion.

the

stress-induced

Furthermore,

i. p.

increase

in

renin

injection of the

and
5-HT2

antagonist LY53857 did not prevent the stress-induced increase in renin
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and corticosterone secretion (Richardson Morton et al., 1986), whereas low
doses of the 5-HT 1 agonist buspirone and ipsapirone inhibited the stressinduced increase in corticosterone and renin secretion (Van de Kar et al.,
1985; Urban et al., 1986; Lorens et al., 1989).
that a non-serotonergic

(or possibly 5-HT 1 )

These studies suggest

mechanism is involved in

stress-induced renin and corticosterone secretion.
Feldman et al. (1987) reported that injection of the serotonergic
neurotoxin 5, 7-dihydroxytryptamine (5, 7-DHT)

into the PVN blocked the

adrenocortical

extra-hypothalamic

responses

to

cortical

and

limbic

stimulation, but had no effect on the adrenocortical response to ether
stress.

Immobilization and cold-exposure stress resulted in four-fold

increases in ACTH-like imrnunoreactivity in plasma.

This increase was

potentiated by i.p. injections of the 5-HT reuptake inhibitor fluoxetine
and

significantly

reduced

by

the

cinanserin (Bruni et al., 1982).

5-HT

antagonists

metergoline

and

These results suggest that 5-HT may play

a role in stress-induced ACTH release.

In contrast, Fuller and Snoddy

(1977) found that pretreatment with fluoxetine did not significantly alter
the increase in plamsa corticosterone levels following swim stress or
insulin-induced hypoglycemia.

However,

fluoxetine

did

enhance

the

corticos terone response produced by an inj ec ti on of L- 5-hydroxytryptophan.
These results suggest that serotonergic neural pathways are involved in
mediating the adrenocortical

response

to

some stressful

stimuli

(i-

mmobilization and cold exposure) but not others (swim stress and insulininduced hypoglycemia).
Beaulieu et al. (1986) support the studies by Bruni et al. (1982).
They found that bilateral lesions of the central nucleus of the amygdala
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resulted in significantly decreased immobilization stress-induced ACTH
secretion with a concomitant increase in serotonergic activity in the PVN
and arnygdaloid nuclei.

Additional studies by Beaulieu et al.

suggest a serotonergic involvement in immobilization stress.

(1987)

In these

studies, bilateral lesions of the central nucleus of the amygdala in
unstressed rats increased the serotonergic activity in the PVN,

dor-

somedial nucleus, anterior hypothalamic area (AHA), cortical and medial
amygdaloid nuclei, and the lateral part of the basal amygdaloid nucleus.
Immobilization stress applied to lesion rats resulted in a decrease in
serotonergic activity to control levels in the PVN, AHA and the dorsomedial nucleus, and below control levels in the ventromedial nucleus.
The serotonergic activity remained elevated in each of the amygdaloid
areas measured, which are rich in glucocorticoid receptors (Beaulieu et
al., 1986).

Glucocorticoids have been reported to down-regulate their own

receptors in a site-specific manner in the amygdala, septum and hippocarnpus, but not in the hypothalamus or pituitary (Sapolsky et al., 1984).
Also noradrenergic cell bodies (Al-A7), serotonergic cell bodies (Bl-B9),
and PNMT-immunoreactive nerve cells of the adrenergic cell groups (Cl-C3)
have been shown to have strong glucocorticoid receptor immunoreactivity
(Harfstrand et al.,

1986).

De Kloet et al.

(1986) have shown that

corticosterone selectively controls the 5-HT 1 receptor density in the
dorsal raphe and dorsal hippocampus.

These studies suggest that serotonin

may modulate the negative feedback of glucocorticoids on stress-induced
ACTH secretion.

A moderate to strong nuclear glucocorticoid receptor

immunoreactivity has been demonstrated in the majority of CRF-immunoreactive neurons of the parvocellular PVN, septohypothalamic thalamus, bed
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nucleus of the stria terminalis, and the medial and central amygdaloid
nuclei (Cintra et al., 1987).

C. Effect of Peripheral Sympathectomy on Stress-Induced Renin and
Corticosterone Secretion
The physiological response to stress involves the release of
catecholamines from the adrenal medulla and sympathetic nerve endings.
These catecholamines stimulate the renal nerves to increase renin output.
It is generally accepted that the sympathetic nervous system mediates the
stress response from the brain to the kidney (Golin et al., 1988; Reid et
al., 1978).

Studies by Van de Kar et al. (1985) have shown that the &-

adrenoceptor antagonist propranolol significantly inhibits but does not
completely block the stress-induced increase in plasma renin activity.
It should be noted, however, that this effect could be mediated by either
central or peripheral &-receptors since propranolol is known to cross the
blood brain barrier (Giarcovich et al., 1984; Lemmer et al., 1985).

To

determine whether stress-induced renin secretion is mediated by the
peripheral sympathetic nervous system, rats were adrenal enucleated and
given weekly injections of 6-0HDA (i.p.).

The adrenal medulla was removed

since it does not effectively take up 6-0HDA.

The effectiveness of the

sympathectomy/adrenal enucleation was verified by determination of plasma
epinephrine (less than 1% of control) and norepinephrine (less than 10%
of control).

The stressor induced a significant increase in plasma renin

activity and concentration.
showed no

Sympathectomized-adrenal enucleated rats

inhibition of the stress - induced increase in plasma renin

activity/concentration or plasma corticosterone levels (Richardson Morton
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et al., 1988).

The data suggest that the sympathetic nervous system and

adrenal catecholamines are not the only mediators of the stress-induced
increase in renin secretion.

5. Central Nervous System Pathways Involved in the
Stress Response
a. Sensory Afferents
With respect to the role of the central nervous system in the
conditioned fear response, it is important to consider how the sensory
stimulus

(pain)

is

transmitted to the cerebral cortex for analysis.

Specialized nerve fibers found throughout the skin serve as end organs
for pain.

These fibers enter the spinal cord and ascend through the

lateral spinothalamic tract to the posteroventral nucleus of the thalamus.
From here the fibers

travel to the appropriate loci in the cerebral

cortex, depending on the somatic origin of the pain message.
The ascending reticular activating system (ARAS) is a network of
interconnective fibers that also travel from the top of the spinal cord
to the thalamus, and eventually to the cortex.

This tract receives major

sensory inputs, and conveys information regarding alertness and excitement.
There appears to be a close connection between pain sensation and
the ARAS.

The midbrain and brainstem reticular formations receive many

pain afferents from the spinothalamic tract.

Studies in animals (Olds

and Olds, 1965) and humans (Gray, 1971) have suggested that stimulation
through electrodes

in

the

generates pain sensation.

periventricular midbrain reticular

system

Other pain reception fibers have been found in
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the thalamic portion of the ARAS.
nuclei and the

thalamic nucleus

Lesions in the thalamic intralaminar
centrum medianum have been shown to

alleviate intractable pain in humans (Gray, 1971).

b. The Limbic System
1. Septo-Hippocampal System
The limbic system,

in particular the septo-hippocampal system,

appears to play a major role in pain reception.

The hippocampus emits a

theta wave (4-9 cps rhythm) as a response to a painful stimulus in the
rat,

and in the emotional states of disappointment and frustration in

humans (Gray, 1971).

This theta wave can be abolished by lesions in the

medial nuclei of the septum, and the thalamic nucleus centrum medianum,
suggesting that the pain input route most likely travels from the midbrain
reticular

formation,

through

the

thalamus,

to

reach

the

septum

and

hippocampus (Gray, 1971).

2. Amygdala
The amygdala is a limbic structure with many interconnections to the
hippocampus (Krettek and Price, 1978).
shown

to

be

involved

in

the

The amygdaloid complex has been

regulation

of

fear-motivated

(Blanchard and Blanchard, 1972; Spevack et al., 1975).

behavior

In addition, the

amygdala appears to play a role in the stress response via the pituitaryadrenal cortical axis.
ticular,

contains

large

The central nucleus of the amygdala,
numbers

of

CRF-containing

terminals (Swanson et al., 1983; Moga and Gray, 1985).
into

the

lateral

ventricles

of

rats

or

dogs

cell

in par-

bodies

and

Injection of CRF

elicits

autonomic

and
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behavioral changes

that are characteristic of the stress or defense

reaction (Brown et al., 1982; Lenz et al., 1987; Britton
et al., 1982).

Electrical stimulation of the amygdaloid complexes results

in an increase in adrenal glucocorticoid secretion in rats (Redgate and
Fahringer, 1973), cats (Redgate, 1970) and monkeys (Mason, 1959).

The

amygdaloid complex is an essential part of the ACTH controlling mechanism
in rats (Knigge, 1961; Allen and Allen, 1974).

Specifically it has been

shown to be necessary for the hypersecretion of ACTH following adrenalectomy (Allen and Allen, 1975).
the

In these studies, lesions which destroyed

direct medial-projecting amgdalo-hypothalamic

fibers

blocked the

hypersecretion of ACTH following adrenalectomy, while lesions of the
septal region, stria terminalis and fornices did not.
Lesions in the amygdaloid central nucleus impaired one-way active
avoidance learning (Werka et al.,

1978), produced marked deficits in

passive avoidance performance (Mcintyre and Stein, 1973; Grossman et al.,
1975),

and

significantly

decreased

ACTH

secretion

immobilization stress (Beaulieu et al., 1987).

in

response

to

Axons from cells in the

olfactory bulb terminate in the amygdala (Powell et al., 1965) and the
medial hypothalamus receives axons from cells in the amygdala (Cowan et
al., 1965).
tical

Bilateral amygdalectomy significantly reduced the adrenocor-

responses

to

sciatic nerve and olfactory stimulation,

without

affecting the corticosterone response to ether or to photic and acoustic
stimulation (Feldman and Conforti,

1981).

This amygdalo-hypothalamic

pathway is believed to play a role in the adrenocortical response to a
number of somatosensory stimuli (Feldman et al., 1975).

The amygdala has

also been shown to play an important role in regulating the cardiovascular
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system during Sidman avoidance stress testing (Galosy et al., 1982).

3. Hypothalamic Ventromedial Nucleus
With

respect

to

the

central

neural

circuits

involved

in

the

fight/flight behavior, de Molina and Hunsperger (1962) described a pathway
in cats that descends from the amygdala along the stria terminalis to the
ventromedial hypothalamus (VMN) with connections to the midbrain central
grey.

Stimulation of sites within the hypothalamus, amygdala and midbrain

central grey could produce defensive attack while other loci immediately
adjacent to those stimulated would produce flight.

When the VMN was

removed, stimulation of the amygdala no longer produced defensive attack,
and removal of the central grey prevented the flight behavior following
hypothalamic stimulation.
In addition, Kling et al. (1958) reported that cats made docile by
lesions in the amygdala could be made ferocious by subsequent lesions in
the VMN.

The converse did not apply - cats first made ferocious by

lesions in the hypothalamus were not affected by a subsequent amygdalectomy.
Based on these and other observations, Gray (1971) suggested that
the midbrain central grey is the ultimate controlling area for either
flight or defensive behavior.

In addition, there is a tonic inhibitory

input to the central grey from the VMN.

Further modulation of this

inhibitory input would come from the amygdala and the septo-hippocampal
system.

Input from the amygdala would prevent the inhibition, resulting

in fight/flight behavior, and the septo-hippocampal input would intensify
passive avoidance behavior.

The resulting behavior

(either passive
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avoidance or fight/flight) would depend on which of the inputs to the VMN
is stronger under a particular set of environmental conditions.

This

scheme would provide a basis for the observation that, in times of danger,
both freezing and fight/flight patterns may be stimulated simultaneously
and alternate rapidly with each other.
Neurons in the VMN have been shown to play a role in stress-induced
renin secretion.
lesions

Gotoh et al. (1988) found that bilateral electrolytic

in the VMN prevented the

following immobilization stress.

increase

in plasma renin activity

Lesions in the VMN led to excessive

levels of food intake and adiposity (Hetherington and Ranson, 1942), and
elicited a variety of metabolic and behavioral disturbances termed the VMN
syndrome, which has become a model for the study of obesity and motivated
behavior (Weingarten et al., 1985; Stellar, 1954).

c. Role of Brain Catecholamines in Stress
A variety of stressors including foot shock (Bliss et al., 1968;
Thierry et al., 1968, Iimori et al., 1981), immobilization (Corrodi et
al., 1968; Tanaka et al., 1981) and ether stress (Vellucci, 1977) have
been

shown

to

decrease

norepinephrine

concentration

and

increase

norepinephrine turnover in the rat brain.
The metabolism of norepinephrine in the rat brain results in the
production of the sulfate conjugates MHPG-S04 , the major metabolite, and
DHPG-S04

(Schanberg et al.,

1968;

Sugden and Eccleston 1971).

The

functional activity of central noradrenergic neurons has been shown to be
directly related to the production of MHPG-S04 (Stone, 1975).

Levels of

MHPG-S04 in rat brain represent a useful index for norepinephrine turnover
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in discrete brain regions (Kohno, 1981) as well as in the whole brain
(Korf et al., 1973; Stone, 1976).
Rats

subjected to

a mild psychological

stressor

(exposure

to

responses of shocked rats) had decreased norepinephrine and increased
MHPG-S04 concentrations preferentially in the hypothalamus and amygdala.
Rats

subjected to

footshock stress had decreased norepinephrine and

increased MHPG-S04 not only in the hypothalamus and amygdala but also the
pons, medulla oblongata and cerebral cortex (Iimori et al., 1981).

This

study suggests that the noradrenergic response to stress varies with the
nature or intensity of the stressor.
Brain noradrenergic systems, in particular the locus coeruleusnoradrenergic system, have been shown to play a role in nociception,
anxiety and fear

(Charney and Redmond,

1983).

The

locus

coeruleus

receives innervation from sensory (pain) pathways in the spinal cord, and
relays information to the cerebral cortex and limbic structures (hypothalamus, hippocampus, amygdala) (Kuhar, 1986).
Rasmussen and Jacobs (1986) have recorded the electrical activity
of noradrenergic neurons in the locus coeruleus of freely moving cats.
During GER training, locus coeruleus units showed a large increase in
activity in response to a stimulus paired with a noxious air puff, whereas
no increase in unit activity is seen in response to a stimulus not paired
with the air puff.

Also, electrical stimulation of the locus coeruleus

in monkeys elicited behavioral responses
experimentally-induced

or

identical

naturally-occurring

fear

to those seen in
states

(Bertrand,

1969).
In humans, drugs that increase noradrenergic function have been
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shown to produce anxiety.
piperoxane

The a 2 -adrenoceptor antagonists yohimbine and

induced anxiety states

Holmberg and Gershon, 1961).

in normal

subjects

(Soffer,

1954;

These studies support the role of brain

norepinephrine in mediating the response to anxiety and fear.
The Kety hypothesis
epinephrine

enhances

cell

(Kety,

1970) proposed that forebrain nor-

firing

in

neurons

that

receive

environmental information to "affectively important events".

afferent
Further,

norepinephrine would produce a "persistent facilitation" of these inputs
which would reinforce the memory process for these events.

The extensive

innervation of the limbic system (especially the hippocampus) by the locus
coeruleus-norepinephrine system suggests that

noradrenergic neurons may

play a role in the memory or cognitive process of stress.

D. HYPOTHALAMIC PARAVENTRICULAR NUCLEUS (PVN)
A. Introduction
The PVN is a bilateral, triangular-shaped nucleus at the dorsal
end of the third ventricle in the hypothalamus.

It is a morphologically

complex structure, with eight clearly distinguishable subdivisions, which
contain as many as thirty different putative neurotransmitters.

Three

major efferent projection sites, arising from separate neuron groups,
include (1) the median eminence, (2) the posterior pituitary and (3) the
autonomic

centers

in

the

brain

stem

Sawchenko, 1983; Saper et al., 1976).

and

spinal

cord

(Swanson

and

This suggests that the PVN serves

as an integrator of endocrine, autonomic and behavioral functions in a
variety of physiological systems.
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B. Morphology
The PVN is composed of distinct parvocellular and magnocellular
divisions

(Krieg,

characterized

the

1932).

Swanson

nucleus

into

and

eight

magnocellular and five parvocellular.

Kuypers
distinct

(1980)

have

further

subdivisions,

three

The anterior magnocellular part of

the PVN is ventromedial to the descending column of the fornix as it
enters

the

hypothalamus

from

the

septum.

The

medial

magnocellular

division is just caudal to the anterior magnocellular level.

The largest

magnocellular division is the posterior magnocellular part.

It first

appears in the ventromedial PVN, just caudal to the medial magnocellular
division.
the

After dorsolateral expansion it forms a compact cell mass at

lateral

margin of

the

nucleus.

Hatton

et

al.,

(1976)

further

subdivide this group by defining two distinct populations of large cells
in the medial and lateral halves of the posterior magnocellular region.
The lateral group contains cells with multiple nucleoli that are larger
and more uniform in orientation, when compared to the medial group.

The

posterior magnocellular cells number from 1300-2000 on either side of the
brain (Olivecrona, 1957; Bodian and Maren, 1951; Swanson and Sawchenko,
1983).
There are five distinct parts of the parvocellular division.
periventricular part,

medial to the rest of the PVN,

vertically-oriented fusiform cells.

The

contains small,

The anterior parvocellular group is

not well-defined but consists of small- to medium-sized cells at the level
of the anterior and medial magnocellular parts.
caudal half of

the

nucleus

is

the

medial

Extending through the

parvocellular part,

which
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consists of densely packed cells.

The dorsal parvocellular part is also

in the caudal half of the nucleus and consists of horizontally-oriented,
medium-sized cells in an elliptical group.

The lateral parvocellular part

of the PVN is in the caudal third of the nucleus and is the lateral
expansion of

the parvocellular part

(the wings).

These

horizontally-oriented, medium-sized and fusiform shaped.

cells

are

At its maximum

extent the lateral parvocellular PVN extends laterally over the descending
column of the fornix, about 750-1000 um from the midline (Swanson and
Sawchenko, 1983).
Cells

in the parvocellular division project primarily to

the

external lamina of the median eminence (Wiegand and Price, 1980; Swanson
et al., 1980) and to the brainstem (dorsal vagal complex) and spinal cord
(Hosoya and Matsushita, 1979; Swanson and Kuypers, 1980).

The PVN is also

known to project to those segments of the thoracic cord thought to contain
sympathetic preganglionic neurons which innervate the kidney (Swanson and
Mc Kellar, 1979).

Cells in the magnocellular division project primarily

to the posterior level of the pituitary gland (Sherlock et al., 1975).
The parvocellular division of the PVN contains about 7000 neurons
in the following distribution: anterior 1650; dorsal 600; lateral 1300;
medial 2175; periventricular 1275 (Sawchenko and Swanson, 1981).

C. Role of the PVN in Behavior
The PVN plays a major role in the control of feeding.

Bilateral

damage to the PVN results in increased levels of food intake and excesive
weight gain (Leibowitz et al.,
elicited by hypothalamic

1981).

injections

This eating behavior can be

of norepinephrine

and other a-
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noradrenergic agonists (Leibowitz, 1975).

In particular, injection of

the a 2 -agonist clonidine into the PVN initiates a feeding response in
satiated rats (Marino et al., 1983).
potent

feeding

response

Goldman et al. (1985) observed a

in satiated animals

norepinephrine or clonidine into the PVN.

following

injection of

This effect was blocked by the

a-antagonist phentolamine as well as the a 2 -antagonists rauwolscine and
yohimbine.

These results suggest that a 2 receptors in the PVN play a role

in mediating feeding behavior.

Leibowitz et al. (1984) have demonstrated

that these a 2 noradrenergic receptors fluctuate in density with respect to
the circadian cycle, exhibiting a unimodal peak at the onset of the dark
cycle, when feeding normally occurs.

This shift in a 2 receptor density may

be correlated with plasma corticosterone levels, which also peak at the
onset of the dark cycle (Krieger and Hauser, 1978; Wilkinson et al.,
Norepinephrine-stimulated feeding behavior was

1979).

prevented by

adrenalectomy and restored by administration of corticosterone (Leibowitz
et al., 1984).

D. Afferent Connections to the PVN
Descending afferent connections to the PVN include a large input
from the limbic system structures, especially the lateral septa! nucleus
and the ventral portion of the subicular cortex, as well as input from
the amygdala, in particular, the medial nucleus (Silverman et al., 1981;
Tribollet

and Dreifuss,

1981).

The

PVN

receives

information from the telencephalic limbic system.

afferent

sensory

The bed nucleus of the

stria terminalis receives a large input from the amygdala (Krettek and
Price, 1978) and smaller projection from the ventral part of the subiculum
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(Swanson and Cowan, 1977).

The bed nucleus has been shown to project to

the PVN by autoradiographic studies (Swanson and Cowan,

1979).

This

projection innervates all parts of the parvocellular division and the
oxytocinergic parts of the magnocellular division (Sawchenko and Swanson,
1981).

Electrophysiological studies have shown that stimulation of the

amygdala or septum can have inhibitory (and sometimes excitatory) effects
on the PVN magnocellular neurons (Renaud and Arnauld, 1979; Koizumi and
Yamashita, 1972; Pittman et al., 1981).
Anterograde autoradiographic techniques were used to describe brain
stem afferents to various PVN regions (McKellar and Loewy, 1981).
parabrachial

nuclei

and

locus

coeruleus

project

periventricular, parvocellular and dorsal divisions.
projects to the lateral,
divisions.
lateral,

medial,

posterior,

the

posterior,

The ventral medulla

dorsal and parvocellular

The Al catecholamine cell group projects to the posterior,

medial and dorsal divisions,

parvocellular and dorsal divisions.
(NTS)

to

The

catecholaminergic

characterized by

an

cell

while the NTS projects to the

The projections from the Al and A2

groups

to

immunofluorescence

the

PVN

have

double-labeling

been

further

procedure

to

determine which anterogradely labeled fibers and terminals in the PVN also
displayed immunoreactive dopamine

~-hydroxylase,

indicating the presence

of catecholaminergic neurons (Cunningham and Sawchenko, 1988). (See Role
of Brain Catecholamines in Corticosterone Secretion)
Studies

using

retrogradely-transported

horseradish

identified cell bodies of neurons that project to the PVN.
bodies were

found in the mediobasal hypothalamus,

the

peroxidase

Labelled cell
limbic system

(lateral septum, posterornedial arnygdala and ventral subiculum) and the
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brain

stem,

including

the

dorsal

raphe

nucleus,

locus

coeruleus,

parabrachial nuclei, NTS and lateral reticular nucleus (Tribollet and
Dreifuss, 1981).

E. Efferent Projections of the PVN
Descending autonomic projections of the PVN were investigated using
the anterograde transport technique of Phaseolus vulgaris leuco-agglutinin
(Luiten et al., 1985).

Two major fiber bundles were described.

One

(fiber bundle 1) leaves the PVN dorsally and runs caudally in a dorsal
periventricular position to reach the midbrain periaqueductal grey, where
a number of terminal boutons are observed.
laterally to join the lateral lemniscus.
dorsal

raphe nucleus,

pontine raphe.

This bundle then courses

Some projections innervate the

the parabrachial nucleus,

locus

coeruleus and

The second group of fibers (fiber bundle 2) runs medially

and caudally from the

PVN and travels

in a position dorsal

to the

transition of the internal capsule and medial forebrain bundle.

In the

midbrain, fiber bundle 2 moves laterally to cover the dorso-lateral pole
of the substantia nigra, and has some terminations in the ventral aspects
of the reticular formation.

At the level of the pons, fiber bundle 2

moves ventrally to join the lateral lemniscus (and bundle 1) to reach the
floor of the brainstem.

Posterior to the pons,

all descending PVN

efferents are now in a ventral position adjacent to the pyramidal tracts.
While in the medulla, some fibers branch off to terminate in the reticular
and medullary raphe nuclei.

Nearly all of the bundle fibers traverse the

lateral

nucleus

reticular nucleus,

ambiguus,

parvocellular reticular

nucleus and area postrema, with an especially dense amount of varicosities
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and terminal boutons in the NTS and dorsal motor nucleus of the vagus.
F. Catecholaminergic Innervation of the Hypothalamic PVN
There is substantive evidence supporting extensive catecholaminergic
innervation of the PVN (Carlsson et al., 1962; Lindvall and Bjorklund,
1974; Hokfelt et al., 1974).

Most of the adrenergic and noradrenergic

innervation to the PVN is provided by (1) the Al and Cl cell groups of the
ventral medulla, (2) the A2 and C2 cell groups in the medial NTS and (3)
the A6 cell group, the locus coeruleus of the pontine central gray.

The

locus coeruleus receives major fiber projections from the Al region, and
projects to the most medial parts of the parvocellular PVN (Swanson et
al., 1981).

G. Neuroactive Substances in the PVN
The colocalization of CRF and vasopressin in the parvocellular PVN
has already been presented (see CORTICOSTERONE: CRF).

These are only two

of many neuroactive substances found in the PVN by immunohistochemical
studies.

Swanson and Sawchenko (1983) have compiled a thorough listing:

Cell Bodies include oxytocin and vasopressin in the magnocellular PVN
(Swaab et al., 1975; Vandesande and Dierickx, 1975); somatostatin in the
periventricular part of the parvocellular PVN (Dierickx and Vandesande,
1979); dopamine in the periventricular and adjoining parvocellular PVN
(Hokfelt et al., 1973); met- and leu-enkephalin in the magnocellular and
pavocellular PVN (Rossier et al., 1979; Finley et al., 1981); neurotensin
in the medial and periventricular parts of the parvocellular PVN (Kahn et
al., 1980); dynorphin coexists with vasopressin in the magnocellular PVN
(Watson et al., 1982); substance Pin the parvocellular PVN (Ljungdahl et
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al., 1978); glucagon in the magnocellular PVN (Tager et al., 1980); renin
in the oxytocinergic parts of the magnocellular PVN (Fuxe et al., 1980);
and ACTH and i-endorphin in the magnocellular PVN (Joseph and Sternberger,
1979;

'Watkins,

1980).

The PVN is also the major source of atrial

natriuretic peptide (ANF)-containing cells that project to the median
eminence (Palkovits et al., 1987).

Double-labelling studies with antisera

to GAD and CRF in the PVN have indicated that a sub-population of CRFcontaining neurons contain the inhibitory neurotransmitter GABA (Meister
et al., 1987).
Nerve

terminals

and

fibers

in

addition

to

norepinephrine,

epinephrine and serotonin (previously described) include "cholinoceptive"
acetylcholine neurons (Kimura et al., 1981); ACTH, i-endorphin and a-MSH
in the parvocellular and oxytocinergic divisions of the magnocellular PVN,
all of which originate in the arcuate nucleus (Joseph, 1980; Bloom et al.,
1978; Jacobowitz and O'Donohue, 1978); VIP in the periventricular part of
the parvocellular PVN (Sims et al., 1980); GABA (Perez de la Mora et al.,
1981); TRH in primarily parvocellular PVN (Hokfelt et al., 1975); and
sparse fibers of LHRH (Jennes and Stumpf, 1980); bradykinin (Correa et
al., 1979); prolactin (Fuxe et al., 1977) and angiotensin II (Fuxe et al.,
1976; Changaris et al., 1978).

a. Neuropeptide Y
The distribution of neuropeptide Y (NPY) immunoreactivity in the
PVN as well as its coexpression in noradrenergic and adrenergic brain stem
groups has been determined with the retrograde transport-double immunohistochemical techniques

(Sawchenko et al.,

1985).

Antisera to phenyl-
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ethanolamine-N-methyltransferase

(PNMT)

was

used

as

a

marker

for

adrenergic neurons, and dopamine-&-hydroxylase (DBH) antisera was used as
a marker for adrenergic and noradrenergic neurons.

The results indicated

a dense NPY input to most parts of the parvocellular PVN in a similar, yet
more extensive distribution than that stained by DBH antisera.
magnocellular

division,

NPY-stained

fibers

were

evenly

In the

distributed

throughout areas containing oxytocinergic and vasopressinergic fibers.
Catecholaminergic fibers were preferentially associated with vasopressinergic fibers.

Combined retrograde transport-double irnrnunohistochemical

labeling studies demonstrated that NPY irnrnunoreactivity is extensively
contained within the adrenergic Cl, C2 and C3 cell groups, with somewhat
less irnrnunoreactivity in the noradrenergic cell groups, mostly limited to
neurons in the Al cell group.
Leibowitz et al. (1986) found that NPY injected directly into the
PVN increased plasma corticosterone levels within 15 minutes of infusion.
The NPY response was similar to that for epinephrine and norepinephrine
(See

CORTICOSTERONE:

Stimulation by Norepinephrine

and Epinephrine).

Also, NPY injected into the third ventricle results in robust feeding
behavior in satiated rats (Allen et al., 1975) in a similar manner to
adrenergic neurotransmitters (See PVN: Role in Behavior).

Studies by Sahu

et al. (1988) suggest that NPY neurons in the brainstem project to the PVN
and mediate the increased sensitivity of the feeding response elicited by
NPY.

CHAPTER III

METHODS

A. Animals
Male Sprague-Dawley rats (200-250 g) were purchased from SascoKing Animal Laboratories

(Oregon, WI).

The rats were housed,

two per

cage, in a temperature (20-22°C), humidity (50-55%) and illumination (12:12
hour light/dark cycle; lights on at 0700 h) controlled room.
food (Wayne Lab Blox,

Lab Mills Inc. , Chicago,

Water and

IL) were available ad

libitum.

B. Surgery
All
mg/kg,

surgery was

i.p.).

performed under pentobarbital

anesthesia

The rats received atropine sulfate (0.4 mg/kg,

reduce respiratory tract secretion and ampicillin ( 50 mg/kg,
prevent infection.

guillotine

i.m.) to
i. m.)

to

Chloramphenicol (1% ophthalmic ointment) was topically

applied around the wound margin.
with a

(50

The rats were euthanized by decapitation

in an area outside the rat room.

Trunk blood was

collected into centrifuge tubes containing 0.5 ml 0.3 M ethylenediamine
tetra acetic acid (EDTA; pH 7.4).
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c.

Electrolytic Destruction of the PVN
Bilateral electrolytic lesions in the PVN were produced by passing

1. 0 mA (D. C.) current for 10 seconds through an intracranial cathode.
anode was clipped to the wound margin.

The

The cathode was a stainless steel

pin (0.25 mm diameter) insulated with Epoxylite except for 0.5 mm of its
tip.

A Kopf stereotaxic apparatus and a Grass DC constant current lesion

maker were used.

The coordinates for the lesion site were 6.0 mm rostral

to lambda, 0.5 mm lateral to the midsagittal suture, and 8.3 mm ventral
to the skull surface, with the incisor bar set at -4. 0 mm.

Control

animals were treated identically except that the electrode was not lowered
into the skull.

The rats were allowed to recuperate from surgery for 14

days, after which time they were subjected to a conditioned emotional
(fear) response paradigm (GER).
below.

The rats were sacrificed by decapitation immediately following the

last CER procedure.
below.

The CER procedure is described in detail

Trunk blood was collected and assayed as described

The brains were removed and saved for histological verification

of the lesion placement.

Eight rats were included in the sham/control as

well as the sham/stress group, while 12 rats per group were used in both
the lesion/control and lesion/stress group.

D. Electrolytic Destruction of the Nucleus Reuniens
Bilateral electrolytic

lesions

of

the nucleus

reuniens

were

produced by passing 1.0 mA current for 5 seconds through an intracranial
cathode while the anode was clipped to the wound margin.

The coordinates

for the lesion site were 5.35 mm rostral to lambda, 0.4 mm lateral to the
midsagittal suture and 8. 0 mm ventral to the skull surface, with the
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incisor bar set at -4.0 mm.

Eight rats were included in the sham/control

as well as the sham/stress group, 10 rats were used in the lesion/control
and 12 rats were used in the lesion/stress group.

The rest of the

protocol for this experiment was identical to that described in the
previous section (Electrolytic Destruction of the PVN).

E. Microiniections of Ibotenic Acid into the PVN
Bilateral stereotaxic microinjections of ibotenic acid (Sigma,
St. Louis, MO) were made using a Kopf stereotaxic apparatus with a 5 µl
Hamilton syringe and a Trent Wells hydraulic microdrive, to allow for a
slow delivery rate.

Ibotenic acid (10 µg/µl)

was dissolved in 0.01 M

phosphosaline buffer (PBS, pH 7.4), and injected in a volume of 0.3 µl
per side over five minutes (Fitzsimons and Ciriello, 1986).

The injection

coordinates (incisor bar at -4.0 mm) were 5.7 mm anterior to lambda, 0.5
mm lateral to the midsagittal suture and 8. 5 mm ventral to the skull
surface.

Control animals received an injection of the vehicle.

After

completion of the injection (five minutes), the needle was left in situ
for

an additional

five

minutes

neurotoxin along the needle track.

to

prevent dorsal

diffusion of

the

The rats were allowed to recuperate

from surgery for 14 days, after which time they were subjected to the CER
procedure.

The rats were sacrificed by decapitation immediately following

the CER procedure, and trunk blood was collected and later assayed. Nine
rats were included in the vehicle/control and eight rats in the vehicle/stress group, while 12 rats per group were used in both the ibotenic
acid/control and ibotenic acid/stress group.
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F. Microinjections of 6-Hydroxydopamine into the PVN
Bilateral stereotaxic microinjections of 6-0HDA-HBr (Regis, Morton
Grove, IL) were made using a Kopf stereotaxic apparatus with a bilateral
cannula constructed of two 26 gauge stainless steel tubes (injectors) with
a 1. 0 mm distance between centers.

The cannula was connected with

flexible tubing to two 25 ul Hamilton syringes and a Sage Instruments
syringe pump, model 355.

6-0HDA was dissolved in 0.1% ascorbic acid in

physiological saline, to prevent autooxidation.

In addition, the vials

of drug solution were kept on ice and covered with aluminum foil to
prevent light exposure.

6-0HDA was injected bilaterally over a five

minute period, in a concentration of 8.0 µg free base in 1.5 µl saline
containing 0.1% ascorbic acid.

Control animals received an injection of

the vehicle (0.1% ascorbic acid in physiological saline). After completion
of the injection,

the needle was left in situ for an additional five

minutes to inhibit dorsal diffusion of the neurotoxin along the needle
track.

The rats were injected with the monoamine oxidase inhibitor

pargyline ( 30 mg/kg,

i. p. ;

Sigma, St. Louis, MO)

surgery, to augment the neurotoxic effect of 6-0HDA.

30 minutes prior to
The coordinates for

the injection site were 5.7 mm rostral to lambda, 0.5 mm lateral to the
midsagittal suture and 8. 7 mm ventral to the skull surface, with the
incisor bar set at -4.0 mm.

The rats were allowed to recuperate from

surgery for 14 days, after which time they were subjected to the CER
paradigm,

described below.

The rats were sacrificed by decapitation

immediately following the last CER procedure.
and assayed as described below.

Trunk blood was collected

The extent of damage to noradrenergic

nerve terminals was determined by immunocytochemical techniques

(see
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below). Eight rats were included in the vehicle/control as well as the
vehicle/stress group, while 12 rats per group were used in both the 60HDA/control and 6-0HDA/stress group.
G. Microinjections of Sotalol into the PVN
Rats were placed in a Kopf stereotaxic apparatus and implanted with
chronic bilateral guide cannulae (Plastic Products, Roanoke, VA).

The

guide cannulae were constructed of two 26 gauge stainless steel tubes with
a 1.0 mm distance between centers.
33 gauge stainless steel wire.

The inner stylets were constructed of

The rats were allowed to recuperate from

surgery for 14 days, and were handled each day following the surgery to
condition them for handling during the injection.

At the end of the 14

day period, the rats were subjected to the CER procedure, described below.
In this particular study, the rats were transported in their home cage to
the CER room, wrapped in a small towel, and held while the dust cap and
stylets were removed and replaced with a 33 gauge bilateral injector.

The

rats received an injection of either vehicle or sotalol, or no injection
at all.

All injections were performed approximately three minutes before

placement in the stress chamber, and 13 minutes before sacrifice.

The

volume (0.5 µl per side) was injected over a 60 second interval.

The

injector remained in situ for an additional 60 seconds to help prevent
dorsal diffusion of the drug.

Sotalol was injected bilaterally (0.5 µl

per side), using two 25 ul Hamilton syringes and a CMA microinjection
pump.
saline.

The concentration of sotalol was 2.0 µg in 0.5 µl of physiological
Vehicle rats received an injection of saline.

The non-injected

rats had their dust caps and stylets removed and injectors placed, but no
injection occured.

The rats were sacrificed by decapitation immediately
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following the CER procedure.
described below.

Trunk blood was collected and assayed as

Fourteen rats were included in the vehicle/control and

vehicle/stress groups. The non-injected/control and non-injected/stress
groups had six rats each.

Sixteen rats were included in the sotalol/-

control and eighteen rats were in the sotalol/stress group.

H. Histology
Lesion placement and drug injection sites were verified histologically.

The brains were preserved in buffered formalin for 48 hours.

brains

were

then

infiltrated with

sucrose

by

successive

intervals in 5% and 10% sucrose solutions, respectively.

four

The
hour

The brains were

stored in a 20% sucrose solution until they were cut on a cryostat (40
micron sections) and stained by the cresyl violet method and inspected by
a microscope to verify the position of the tip of the needle or extent of
lesion damage.

I. Immunocytochemistry
The brains from the 6-0HDA-treated rats were fixed for five hours
in a solution containing 4% paraformaldehyde-0.05% glutaraldehyde in 0.10
M phosphate buffer, pH 7.5 at 4°C.

They were then transferred to a 15%

sucrose PBS solution where they were stored overnight at 4°C (Furness et
al., 1978).

The brains were then mounted in a cryostat, frozen and cut

into 40 micron sections.

These sections were floated in 0.05 M PBS and

mounted on slides and allowed to air dry.

The slides were then placed in

air-tight slide boxes and kept at 0°C until processed (approximately 48
hrs).

Sections were then washed and incubated in immunocytochemistry
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(ICC) buffer consisting of phosphosaline buffer (PBS), 1.0% normal goat
serum (from second antibody host species), 0.1% gelatin, 0.01% thimerosal,
O - 0.002% neomycin, and 0 - 0.2% triton X-100.
consecutively

in

medullary dopamine

the

primary

antibody,

~-hydroxylase

Sections were incubated

rabbit

anti-bovine

adrenal

(DBH, 1:1000 dilution) for 12 hours in

humidity-controlled chambers at 4°C.

The DBH antibody was obtained from

two sources: (1) Eugene-Tech, Allendale, NJ and (2) Dr. Eric Schweitzer,
Madison, WI.

The two DBH antibodies gave nearly identical results when

tested on control rats.

This incubation was followed by addition of a

1:50 dilution of goat anti-rabbit IgG followed by an incubation with 1:200
peroxidase-antiperoxidase (rabbit PAP) solution for 30 minutes at room
temperature.
0.02 M PBS.
mg/100

ml

Sections were washed between each immune incubation with
Bound peroxidase was visualized by incubating sections in 25
diaminobenzidine

tetrahydrochloride

hydrogen peroxide for 5-7 minutes.

(DAB-4HC1)

and

0.01%

To increase sensitivity this solution

also included 2.5% nickel ammonium sulfate.

Sections were washed, mounted

with cover slips, and viewed on a Leitz Ortholux photomicroscope.

J. Stress (GER) Procedure
In each of the experiments, the rats had at least a two-week postoperative

recovery period before being subjected to

emotional response (GER) paradigm.

the conditioned

The GER was performed in a ten-inch

square, clear Plexiglass chamber with a grid floor composed of stainless
steel rods (0.3 inches in diameter) spaced 0.5 inches apart.
was illuminated by a 7.5 W incandescent lamp.

The chamber

The chamber was located

inside a larger, rectangular sound-attenuating box equipped with a two-
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way mirror (13" x 9") so that the rat's behavior could be observed.

The

sound-proof box also had a small fan in the back wall for ventilation.
Scrambled current (0.8

mA

D.C.) shock for 10 seconds was delivered through

the grid floor by a Grayson-Stadler shock generator.
The rats were assigned at random before testing to a particular
treatment group (control or stress) such that cage mates were members of
the same group.

Cage mates were tested sequentially and at the same time

each day (between 10:00 and 15:00 hours) on four consecutive days.
On each day, the rats were transported ten feet from their living
quarters to the stress chamber.

Ten minutes following placement in the

chamber, the experimental animals received an inescapable foot shock, then
were returned to their home cage.
consecutive days.

This procedure was repeated for three

The behavior of the rats was observed on days 3 and 4

of the CER paradigm.

It was apparent from these observations that the

stressed rats had learned that their placement in the chamber would be
followed by a foot shock.

By the third day, in contrast to the control

animals, the stressed rats defecated, urinated and demonstrated freezing
(no movement) behavior.

On the fourth day, after 10 minutes in the test

chamber, instead of receiving shock the rats were removed, transported to
a third area outside
decapitation.

the

stress

room and immediately sacrificed by

The control rats were treated identically except that shock

was not administered at any time.
The stress chambers were cleaned carefully after each rat had been
tested.

Fecal boli and urine were removed, as well as washing the grid

floor and sides of the plexiglass chamber.
analgesic effect described by Fanselow (1985)

This was to prevent the
that can occur when an
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unstressed rat is placed in a chamber containing the odor of a rat that
has received an electric shock.

Rats have been shown to release an

innately recognized odor in response to many types of aversive events
(Brown, 1979).

In particular, aversive electric shock elicits an odor

that conspecifics can discriminate from the odors of unstressed rats
(Valenta and Rigby, 1968).

These odors have been shown to interfere with

the acquisition of one-way shock avoidance (Dua and Dobson, 1974).

K. Biochemical Determinations
1. Plasma Renin Activity (PRA)
PRA was measured by radioimmunoassay for generated angiotensin I
(Haber et al., 1969; Stockigt et al., 1971).

The pH of the samples was

reduced to pH 6.5 by addition of 0.5 ml of 0.5 M phosphate buffer pH 6.0.
The conversion of angiotensin I

to angiotensin II was prevented by

addition of 0.025 ml of 8-hydroxyquinoline (8-HQ; 10% suspension in 0.3
M EDTA; 3.4 mM final concentration; Mallinckrodt, St. Louis, MO) and 0.020
ml of phenylmethylsulfonyl fluoride (PMSF; 5 g in 150 ml ethanol; 2.5 mM
final concentration; Sigma, St. Louis, MO).

Plasma samples were incubated

for three hours at 37°C to generate angiotensin I (AI).

The incubation was

stopped by immersion of the samples in boiling water for three minutes.
The radioimmunoassay of AI was performed with an antiserum against AI at
a dilution of 1:30,000, and a total binding of 35%.

The antibody was

added to the samples in a volume of 0.3 ml (AI antiserum in a 0.1 M Tris
buffer, pH 8.0, containing 0.1% gelatin) and incubated overnight at 4°c.
The tracer ( 125 I

labelled AI) was added to the samples the following

morning, in a volume of 0.4 ml per tube, approximately 10,000 counts per
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minute per tube.

On the next day,

the antibody-bound (iodinated AI)

tracer was separated from the free tracer by addition of O. 5 ml of a
suspension containing activated charcoal and dextran T500
Piscataway, NJ) and centrifugation at 2000 x g for 15 minutes.

(Pharmacia,
The pellet

containing the unbound tracer was counted on a micromedic 4/200 plus
automatic

gamma

counter

which was

microfazer) to an IBM PC-AT computer.

connected via

a

buffer

(Quadram

The data were analyzed by a program

(RIA-AID) that was purchased from Robert Maciel Associates (Arlington,
MA).

The sensitivity limit of the RIA is 10 pg AI per tube and the intra-

assay variability was 4.0%.
Kar et al., 1984).

The inter-assay variability was 7.4% (Van de

The tracer (AI; Beckman, Arlington Heights, IL) was

iodinated via the chloramine T (Sigma, St. Louis, MO) method (Greenwood
et al., 1963).

Phosphate buffer (0.05 M; 0.02 ml), 12 µl AI (0.5 µg/µl)

and 20 µl chloramine T (3.5 mg/ml phosphate buffer) were added to the vial
containing the

125

I and mixed for three seconds.

This was immediately

followed by addition of 25 µl of sodium metabisulfite (4. 5 mg/ml phosphate
buffer;

J. T.

reaction.
exchange

Baker Chemical Co. ,

Phillipsburg,

NJ)

to terminate the

Chromatography of the iodinated AI was performed first by ion
(Biorad AG-1X4,

200-400

mesh)

chromatography.

The

column

consisted of a siliconized Pasteur pipette (5 3/4"; Scientific Products)
with a small amount of glass wool placed in the tip of the pipette to
support the anion exchange res in.

Fractions (12 drops per tube) were

collected from the column and the radioactivity in each tube was measured.
The radioactive peak fractions eluted off this column were then placed on
a Sephadex G-15 column for gel filtration and eluted with 0.05 N acetic
acid containing 0.1% bovine serum albumin (Sigma, St. Louis, MO).

Two ml
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fractions

were

collected

radioactivity.

off

the

Sephadex

column

and

measured

for

The tubes containing the radioactive AI were pooled and

stored at -10°c.

2. Plasma Renin Concentration (PRC)
Renin

is

the

enzyme

substrate angiotensinogen,
Angiotensin I.

responsible

produced by

the

for

the

conversion

liver,

of

the

to

The measurement of plasma renin activity reflects the

concentration of renin as well as renin substrate (angiotensinogen) in
plasma.

The normal angiotensinogen concentration is only about or less

than Km (Reid et al.,

1978) and thus much less than the concentration

required to generate AI at maximum velocity (Vmax).

Studies by Van de

Kar et al. (1981) have demonstrated that 5-HT dependent changes in plasma
renin activity are not accompanied by changes in plasma angiotensinogen
levels.

However,

since electrolytic lesions in the PVN could cause a

reduction in corticosterone levels, this could lead to decreased secretion
of angiotensinogen from the liver.

This would cause plasma renin activity

values to be low even when renin levels were unaffected.

The assay for

plasma

a

renin

concentration

involves

the

addition

of

saturating

concentration of exogenous renin substrate to the samples such that renin
is

working

eliminates

at Vmax.
the

The

possibility

measurement
that

of plasma

decreased

renin concentration

substrate

levels

would be

misinterpreted as decreased levels of renin.
The renin substrate was plasma from nephrectomized rats which
received dexamethasone (0.2 mg/rat) 24 hours before sacrifice.

The plasma

samples (0.2 ml) received 0.1 ml of nephrectomized plasma, 0.1 ml of 0.5
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M phosphate buffer pH 6.0, and 5 µl each of PMSF and 8-hydroxyquinoline
(to a final concentration of 2.5 mM and 3.4 mM,
mixture was incubated at 37°C for one hour.

respectively).

The

The reaction was stopped by

immersion of the tubes in a boiling water bath for three minutes.

The

radioimmunoassay of AI is as described for PRA.

3. Plasma Angiotensinogen
This radioimmunoassay is similar to that for PRC except that a
saturating amount of the enzyme renin (from kidney homogenates) is added
to the plasma samples before incubation to allow conversion of endogenous
renin substrate to AI (Menard and Catt, 1972).

Therefore any differences

in the production of AI will be attributed to differences in substrate,
not enzyme levels.
The plasma samples (0.1 ml) received 0.1 ml of 0.5 M phosphate
buffer pH 6.0, 0.1 ml renin (from rat kidneys homogenized in cold water
1 g/ml at a 1:1,000 dilution),

and 5 µl each of PMSF and 8-HQ.

mixture was incubated at 37°C for one hour.

The

The reaction was stopped by

immersion of the tubes in a boiling water bath for three minutes.

The

remainder of the radioimmunoassay for AI is as described for PRA.

4. Plasma Corticosterone
Corticosterone radioimmunoassays on unextracted plasma (5 and 10
µl) were performed using procedures and antiserum from Radioassay Systems
Laboratories

(Carson,

CA).

The binding proteins were

denatured by

incubation of the sample tubes and assay buffer in a hot water (80°C) bath
for twenty minutes.

The standards were made of serial dilutions of
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corticosterone (Steraloids, Wilton, NH) in assay buffer.
(catalog

#

1472, lot

#

The antiserum

3R3-38) was used at a final dilution of 1:10,500

and total binding of 40%.

The incubation of the samples (or standard)

with the antiserum and tracer (corticosterone l,2,6,7- 3H(N)-; NET-399,
New England Nuclear) occurred overnight at 4°C.

The antibody-bound tracer

was separated from the unbound tracer by addition of a charcoal-Dextran
T70 suspension, centrifugation, and decanting of the supernatant into
scintillation vials containing 5 ml of a scintillation cocktail (4 g of
Omnifluor in 1 liter of toluene).

The samples containing the supernatant

and scintillation cocktail were counted in a Packard liquid scintillation
The data were stored on a diskette by a Diskstore (United

counter.

Technologies,

Packard)

and were

analyzed using the RIA-AID

(Robert Maciel Associates, Arlington, MA).

software

The intra- and inter-assay

variability were 4.5% and 11.9% respectively (Van de Kar et al., 1985).

L. Statistics
The data are reported as mean ± S. E .M.
mean).

The sample mean was the average of the number of animals in each

group (n).
below.

(standard error of the

The standard error of the mean was calculated as described

Statistical analyses of the data was performed by a two-way

analysis of variance (ANOVA).
Student Newman-Keul's

Individual group means were compared by

multiple range test (Steel and Torrie, 1960).

The most common measurement of central tendency for given samples
of a population is the arithmetic average or mean.
measure of central tendency,

it is important to

samples differ in variability.

In addition to the
be aware of how the

This measure is the variance, or its
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square root, the standard deviation (S.D.).

This variance will provide

information as to whether an observation is an ordinary or an unusual
value in a specified population, giving a small value when the observations cluster closely about a central value, and a larger value when they
are

spaced widely.

The

sum of

squares

deviations from the arithmetic mean.
degrees of freedom.

is

the

The quantity (n-1)

the

squared

is known as

Sum of squares is divided by degrees of freedom to

give unbiased estimates of the population variances.
are also subject to variation,
reported.

sum of

Since sample means

the standard error of the mean is also

It is calculated by dividing the S.D. by the square root of the

number of observations in the mean.

1. Analysis of Variance (ANOVA)
Analysis of variance is defined by Steel and Torrie

(1960)

as

" ... an arithmetic process for partitioning a total sum of squares into
components associated with recognized sources of variation."

Using this

type of test, the data are classified according to their treatment group.
With respect to the present studies, a two-way analysis of variance was
the appropriate test,

since the animals were subjected to two separate

treatments: (1) surgical (or drug) and (2) behavioral (stress).
The error mean square is an average of the components contributed
by

the

treatments.

It

is

an

estimate

observations of the same treatment group.

of a

common variation among

Treatment mean square is an

independent estimate of the variance when the null hypothessis is true.
F is

defined as

variance,

thus,

the

ratio

of two

independent estimates

of the

same

the F value is obtained by dividing the treatment mean
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square by the error mean square.

Once F has been calculated,

it is

compared with the tabular F at the appropriate degrees of freedom at the
.05 (5%) probability level.

If the calculated F is greater than the

tabulated F, then the null hypothesis (no difference between population
means)

can be rejected and it can be concluded that there are real

differences among treatment means.

With respect to the two-way ANOVAS of

the present studies, three F values were obtained:

Fa for the surgical or

drug treatment, Fb for the stress treatment, and Fa x b for the interaction
between the drug and stress treatments.

The F value reported was the one

that accounts for interaction between both the stress and surgical/drug
treatment groups.

2. Student-Newman-Keuls' Test
Multiple comparison tests can be used to compare each treatment
mean with every other treatment mean.

Student-Newman-Keuls' test is a

multiple

the

range

differences;

test

" ... for

judging

significance

of

a

set

of

it permits decisions as to which differences are significant

and which are not ... Error rate is seen to apply neither on an experimentwise nor a per-comparison basis since a particular range test may be made
for one or more comparisons in a particular experiment" (Steel and Torrie,
1960).

This test also takes into account the number of treatments in the

experiment.

To perform the Newman-Keuls' test, the mean square error from

the ANOVA is divided by the harmonic mean (average number of n per group).
The square root of this number is Sx, the standard error of the mean.
a tabular value, q, is selected.

Next

This value is based on a .05 level of

probability, and the appropriate p (number of treatment means) and degrees
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of freedom.

Q is multiplied by Sx to give a range of significance.

If the

distance between two means is greater than the range of significance, then
the difference between the two means is significant at the 0.05 probability level.

CHAPTER IV

RESULTS

A. Electrolytic Lesions in the PVN
Figure 1 is a coronal section of an intact PVN, stained with cresyl
violet.

Figure 2 shows an electrolytic lesion in the PVN. These lesions

did not extend caudally beyond the PVN, and the dorsomedial
intact.

There was

some damage

nucleus was

to the caudal aspect of the anterior

hypothalamic area, as in Figure 2.

This was not evident in all cases.

The lesions did not extend laterally to the fornix.

Only lesions which

destroyed 90% or more of the PVN and did not extend dorsally into the
thalamus were considered in the statistical evaluation of hormonal data.
Following histological verification,

the lesion control/group consisted

of five rats, while the lesion/stress group consisted of seven rats with
accurate and complete PVN lesions.

One rat did not survive the anesthesia

in the sham/control group, making the total for this group seven rats.
Electrolytic
increases

in

concentration
(Figure 5).

lesions

plasma

renin

(PRC)

(Figure

in

the

PVN

activity
4),

and

prevented

(PRA)

(Figure

in plasma

the
3),

stress-induced
plasma

corticosterone

renin
levels

By comparison, rats with lesions which missed the PVN (n=S),

but destroyed areas rostral to the PVN, showed no inhibition of the effect
of stress on PRA (24.0

± 3.2), PRC (33.7 ± 6.2) and corticosterone (29.3

± 6.1) levels.
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FIGURE 1

CORONAL SECTION OF RAT
BRAIN WITH AN INTACT
PARAVENTRICULAR NUCLEUS

FIGURE 2

CORONAL SECTION OF RAT BRAIN
WITH AN ELECTROLYTIC LESION
IN THE PARAVENTRICULAR NUCLEUS
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The effect of stress on plasma renin activity in rats with electrolytic
PVN lesions. The data represent mean± S.E.M., n=7 for the sham/control
group, n=6 for the sham/stress group, n=5 for the lesion/control group,
and n=7 for the lesion/stress group.
* Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 5.7 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of the lesion F(l, 21) 10.789; stress F(l,21) = 14.617; and lesion*stress interaction F(l,21) 9. 031.
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FIGURE 4
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FIGURE 5
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The effect of stress on plasma corticosterone levels in rats with
electrolytic PVN lesions. The data represent mean± S.E.M., n=7 for the
sham/control group, n=6 for the sham/stress group, n=5 for the lesion/control group, and n=7 for the lesion/stress group.
* Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 7.0 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of stress F(l,21) = 11.06;
and lesion*stress interaction F(l, 21) = 14. 245.
The lesion did not
produce a significant effect F(l,21) = 0.64.
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B. Electrolyic Lesions in the Nucleus Reuniens
In a control experiment, lesions in the thalamic nucleus reuniens
were made,

dorsal and caudal to the PVN.

These lesions were small,

discrete and did not extend to the region of the third ventricle.and the
PVN (Figure 6).

Following histological verification of placement in the

nucleus reuniens, five rats were included in the lesion/control and six
rats included in the lesion/stress group.

There were six rats in the

sham/stress group, and eight rats in the sham/control group.
Electrolytic lesions in the nucleus reuniens did not prevent the
stress-induced increase in plasma renin activity (Figure 7) or plasma
renin concentration (Figure 8).

The stress-induced increase in plasma

corticosterone levels was attenuated but not completely blocked by nucleus
reuniens lesions (Figure 9).

It is possible that this lesion interrupted

afferent fibers to the PVN that are involved in stimulating CRF neurons
in the PVN.

Stressed rats in which the lesions missed both the nucleus

reuniens and the PVN (n=S), had hormonal values similar to the sham/stress
group and the group in which the nucleus reuniens was destroyed (PRA 14.3

± 3.6; PRC 13.5 ± 1.8; and corticosterone 18.2 ± 1.7).

99

FIGURE 6

CORONAL SECTION OF RAT BRAIN WITH AN
ELECTROLYTIC LESION IN THE THALAMIC NUCLEUS REUNIENS
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The effect of stress on plasma renin activity in rats with electrolytic
lesions in the nucleus reuniens. The data represent mean± S.E.M., n-8
for the sham/control group, n=6 for the sham/stress group, n=5 for the
lesion/control group and n=6 for the lesion/stress group.
* Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 6.4 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of stress F(l,21) = 11.58;
but not of the lesion F(l,21) = 0.761 or lesion*stress interaction F(l,21)
- 0.92.
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The effect of stress on plasma renin concentration in rats with electrolytic lesions in the nucleus reuniens. The data represent mean± S.E.M.,
n=8 for the sham/control group, n=6 for the sham/stress group, n=S for the
lesion/control group and n=6 for the lesion/stress group.

* Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 7.4 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of stress F(l,21) = 10.291;
but not of the lesion F(l,21) - 0.042 or lesion*stress interaction F(l,21)
= 1.109.
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The effect of stress on plasma corticosterone levels in rats with
electrolytic lesions in the nucleus reuniens. The data represent mean±
S.E.M., n=7 for the sham/control group, n=6 for the sham/stress group,
n=5 for the lesion/control group and n=6 for the lesion/stress group.

* Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 6.5 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of stress F(l,20) - 10.29;
but not of the lesion F(l,20) = 0.601 or lesion*stress interaction F(l,20)
= 1. 83.
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c. Injection of Ibotenic Acid into the PVN
Figure 10 is a section of an intact PVN stained with cresyl violet.
Figure 11 shows the needle tracks and destruction of neurons in the PVN
following

an

injection of

ibotenic

acid.

Acceptable

lesions

were

restricted to the PVN and, compared with control sections, showed greater
than 50% cell loss.

Following histological verification of the injection

site and evaluation of the hormonal data, there were seven rats included
in both the vehicle/control and vehicle/stress group.

Four rats in the

ibotenic acid/control and six rats in the ibotenic acid/stress group were
considered accurate PVN lesions.
Ibotenic acid-induced lesions in the PVN prevented the stressinduced increase in plasma renin activity (Figure 12) and plasma renin
concentration (Figure 13).

Stress-induced increases in corticosterone

levels also were prevented by ibotenic acid lesions of neurons in the PVN
(Figure 14).

By comparison, stressed rats with ibotenic acid injections

which missed or caused unnoticeable damage to neurons in the PVN (n=6) had
PRA (28.9 ± 3.8), PRC (35.5 ± 4.5) and corticosterone levels (16.9 ± 1.9)
which were indistinguishable from the vehicle/stress group.

Thus far, the

data suggested that cell bodies in the PVN are involved in stress-induced
renin and corticosterone secretion.

104

FIGURE 10

INTACT PARAVENTRICULAR NUCLEUS
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PARAVENTRICULAR NUCLEUS FOLLOWING
BILATERAL INJECTION OF IBOTENIC ACID
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The effect of stress on plasma renin activity in rats with ibotenic acid
lesions in the PVN.
The data represent mean ± S. E .M., n=7 for both
vehicle groups, n=4 for the ibotenic acid/control group, and n=6 for the
ibotenic acid/stress group.
* Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 10.5 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of the drug F(l,20) = 4.959;
stress F(l,20) = 9.488; and drug*stress interaction F(l,20) = 6.063.
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The effect of stress on plasma renin concentration in rats with ibotenic
acid lesions in the PVN. The data represent mean± S.E.M., n=7 for both
vehicle/control and vehicle/stress groups, n=4 for the ibotenic acid/control group, and n=6 for the ibotenic acid/stress group.
* Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 13.5 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of the drug F(l,20) = 5.063;
and stress F(l,20) = 8.069. The drug*stress interaction F(l,20) - 3.619
was not significant.
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The effect of stress on plasma corticosterone levels in rats with ibotenic
acid lesions in the PVN. The data represent mean± S.E.M., n=7 for both
vehicle/control and vehicle/stress, n=4 for the ibotenic acid/control
group, and n=6 for the ibotenic acid/stress group.
* Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 4.3 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of the drug F(l,21) = 12.273;
and stress F(l, 21)
19. 645.
The drug*stress interaction was not
significant F(l,21) = 3.198.
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o.

Injection of 6-0HDA into the PVN
Figure 15A shows a coronal section of the PVN following vehicle

injection and

staining with dopamine

~-hydroxylase

(DBH)

antiserum.

Figure 15B shows a coronal section of the PVN following 6-0HDA injection
and staining with DBH antiserum, showing loss of DBH immunoreactivity.
In general, there was a 60-80% reduction in DBH staining (as compared to
vehicle rats)

in a 500-1000 micron area that encompassed the PVN and

anterior hypothalamus,
hypothalamus.

but did not spread as

far as

the mediobasal

Following immunocytochemical and histological verification,

the vehicle/control and 6-0HDA/control groups consisted of seven rats
each,

the vehicle/stress group consisted of six rats,

and the 6-0H-

DA/stress group had five rats.
The stress (GER) procedure produced a significant increase in plasma
renin acivity and concentration as well as increasing plasma corticosterone levels in rats which received an injection of vehicle or noninjected animals.

Injection of 6-0HDA into the PVN prevented the effect

of stress on plasma renin activity (Figure 16) and plasma renin concentrati on

(Figure 17) .

In addition the effect of stress on plasma cor-

ticosterone levels was also blocked (Figure 18).

Since 6-0HDA injections

into the PVN prevented the stress - induced increase in corticosterone
levels, it is possible that this caused decreased secretion of the renin
substrate (angiotensinogen) from the liver.

This would cause PRA values

to be low even though renin levels were unaffected.

To test this, in

110

addition to measurements of PRC,
determined (Figure 19).
groups.

plasma angiotensinogen levels were

There were no differences observed between the

This suggested that neither stress nor 6-0HDA injections affected

plasma levels

of renin substrate.

Thus

far

the data suggest

that

catecholaminergic neurons or nerve terminals in the PVN play a role in the
stress-induced increase in renin and corticosterone secretion.
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FIGURE lSA

CORONAL SECTION FROM RAT INJECTED WITH
VEHICLE AND STAINED WITH DBH ANTISERUM

CORONAL SECTION FROM RAT INJECTED WITH
6-0HDA AND STAINED WITH DBH ANTISERUM,
SHOWING LOSS OF DBH IMMUNOREACTIVITY
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The effect of stress on plasma renin activity in rats with 6-0HDA lesions.
The data represent mean ± S.E.M.;
n=7 for vehicle/control, n=6 for
vehicle/stress, n=7 for 6-0HDA/control and n=5 for 6-0HDA/stress.
*Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 5.48 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of the drug F(l,21) = 13.576;
stress F(l,21) = 35.595; and drug*stress interaction F(l,21) = 12.427.
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FIGURE 17
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The effect of stress on plasma renin concentration in rats with 6-0HDA
lesions. The data represent mean± S.E.M.; n=7 for vehicle/control, n-6
for vehicle/stress, n=7 for 6-0HDA/control and n-5 for 6-0HDA/stress.
*Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 12.9 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of the drug F(l,21) = 6.939;
stress F(l,21) = 24.623; and drug*stress interaction F(l,21) = 6.059.
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The effect of stress on plasma corticosterone levels in rats with 6-0HDA
lesions. The data represent mean± S.E.M.; n-7 for vehicle/control, n-6
for vehicle/stress, n=7 for 6-0HDA/control and n-5 for 6-0HDA/stress.
*Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 10.0 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of stress F(l,21) = 9.422.
There were no significant effects of either the drug F(l,21) = 0.194 or
drug*stress interaction F(l,21) = 3.371.
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FIGURE 19
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The effect of stress on plasma angiotensinogen levels in rats with
6-0HDA lesions.
The data represent mean± S.E.M.;
n-7 for vehicle/control, n=6 for vehicle/stress, n=7 for 6-0HDA/control and
n=5 for 6-0HDA/stress.
No significant differences found among the groups, p < 0.05. A minimal
difference of 33.l would be required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates no significant effects of the drug F(l, 21) 1. 395; stress F(l, 21) = 0. 072; and drug*stress interaction F(l, 21) 0. 721.
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E. Injection of Sotalol into the PVN
Figure 20 shows a coronal section of the PVN stained with cresyl
violet following a bilateral injection of sotalol into the PVN.

Only rats

in which the tip of the cannula was immediately dorsal to the border of
the PVN, or inside the dorsal PVN, were acceptable.

In several rats, the

cannulae ended inside the PVN, producing large mechanical lesions.

These

rats were excluded from the statistical analysis of the hormonal data.
Following histological verification of the injection site, eight rats were
used

in

the

vehicle/control,

five

rats

in vehicle/stress

and non-

injected/stress, and four rats in the non-injected/control group.

There

were six rats used in the sotalol/control group and eight rats in the
sotalol/stress group.
Figures 21 and 22 show the effect of stress on plasma renin activity
and plasma renin concentration, respectively, in rats injected with either
vehicle or sotalol, or in non-injected rats.

Stress-induced increases in

PRA and PRC were not prevented by injection of sotalol.
stress-induced

increase

in

corticosterone

levels

injections of sotalol into the PVN (Figure 23).

was

However, the
prevented

by
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FIGURE 20

CORONAL SECTION OF THE PARAVENTRICULAR NUCLEUS
FOLLOWING BILATERAL INJECTION OF SOTALOL
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FIGURE 21
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The effect of stress on plasma renin activity in rats injected with either
vehicle or sotalol, or in non-injected rats. The data represent mean±
S.E.M.;
n=8 for vehicle/control, n=4 for vehicle/stress, n=6 for
sotalol/control, n=7 for sotalol/stress, n=4 for non-injected/control and
n=5 for non-injected/stress.
*Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 8.42 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of stress F(l,28) - 32.526;
but not of the drug F(2,28) = 0.871 or drug*stress interaction F(2,28) 0.528.
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FIGURE 22
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The effect of stress on plasma renin concentration in rats injected with
either vehicle or sotalol, or in non-injected rats. The data represent
mean± S.E.M.; n=8 for vehicle/control, n=4 for vehicle/stress, n=6 for
sotalol/control, n=7 for sotalol/stress, n=4 for non-injected/control and
n=5 for non-injected/stress.
*Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 9.6 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of stress F(l,28) - 17.357;
but not of the drug F(2,28) = 0.249 or drug*stress interaction F(2,28) 0.553.
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The effect of stress on plasma corticosterone levels in rats injected with
either vehicle or sotalol, or in non-injected rats. The data represent
mean± S.E.M.; n=8 for vehicle/control, n=4 for vehicle/stress, n-6 for
sotalol/control, n=7 for sotalol/stress, n=4 for non-injected/control and
n=S for non-injected/stress.
*Significant difference from the corresponding control group, p < 0.05.
A minimal difference of 8.6 is required between the means by the StudentNewman-Keuls' test.
Two-way ANOVA indicates a significant effect of stress F(l,28) = 9.823.
No significant effect is seen with the drug F(2,28) - 1.724 or drug*stress
interaction F(2,28) = 1.411.
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F. Comparison of Normal Plasma Pools to Experimental Controls
Pooled plasma samples for "normal" and "high" PRA or "normal" and
"high" corticosterone levels are run routinely with each respective assay.
The pooled plasma samples are compiled from rat plasma that has been
previously assayed and classified within the range of "normal" or "high"
A random sample of these

based on its corticosterone or PRA value.

values, taken from assays run between 1986 and 1989, gave the following
values (mean± standard error of the mean):
"normal" PRA
"high" PRA

7.6 ± 0.5
23.6 ± 2.8

(n
(n

23)
23)

"normal" corticosterone
"high" corticosterone

8.9 ± 1.1
20.9 ± 2.0

(n
(n

13)

10)

The pooled values for "normal" PRA and corticosterone are very
similar to previously published values for PRA and corticosterone in
untested control animals, shown below.
Untested Control Rats
PRA
Corticosterone

7.1 ± 1.2
8.9 ± 2.1

(Van de Kar et al., 1985)
(Van de Kar et al., 1985)

The normal plasma pool values were compared to the means of the
sham-

or vehicle-treated groups

dissertation.

in each of the experiments of this

ANOVA and Newman-Keuls' Multiple Range Test were run to

determine if significant differences between the groups exist.

With

respect to plasma renin activity, the data are shown on the following
page:
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Table 1.
Comparison of Mean Values:
Normal PRA Pool versus Experimental
Sham- or Vehicle-Treated Groups
Group Number

Description

Mean + Std.Error

n

4

6-0HDA Expt. Vehicle/Control

3.6 ± 0.8

7

1

Electrolytic PVN Sham/Control

4.5 ± 0.6

7

5

Sotalol Expt. Vehicle/Control
+ Non-injected/Control

6.3 ± 0.5

12

2

Electrolyt. N. Reun. Sham/Cont.

6.4 ± 0.4

8

6

Normal PRA Pool

7.6 ± 0.5

23

3

Ibotenic Expt. Vehicle/Control

9.2 ± 0.9

7

Standard Error of Treatment Means - 0.74

123

Table 2
Newman-Keuls' Multiple Range Test for PRA

Treatment

vs.

Treatment

Difference

Group 4

Group 1

0.94

Group 4

Group 5

2. 71

Group 4

Group 2

2.82

Group 4

Group 6

4.06

Group 4

Group 3

5.62

Group 1

Group 5

1. 77

Group 1

Group 2

1. 88

Group 1

Group 6

3.11

*

Group 1

Group 3

4.68

*

Group 5

Group 2

0.11

Group 5

Group 6

1. 34

Group 5

Group 3

2.91

Group 2

Group 6

1. 23

Group 2

Group 3

2.80

Group 6

Group 3

1.56

Sig .OS

*
*
*
*

*
*
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The means of the experimental vehicle- or sham-treated goups were
not significantly elevated above the normal PRA plasma pool.

However,

two experimental groups had PRA values lower than the normal PRA pool
levels.
With respect to corticosterone, the data are as follows:

Table 3
Comparison of Mean Values:
Normal Corticosterone Pool versus Experimental
Sham- or Vehicle-Treated Groups
Group Number

Description

Mean + Std.Error

!!

3

Ibotenic Expt. Vehicle /Control

6.5 ± 0.5

7

4

6-0HDA Expt. Vehicle/Control

7.1 ± 0.5

6

6

Normal Corts Pool

8.9 ± 1.1

13

1

Electrolyt. PVN Sham/Control

9.3 ± 2.3

7

2

Electrolyt. N. Reun. Sham/Cont.

12.8 ± 0.9

7

5

Sotalol Expt. Vehicle/Control
+ Non-injected Control

12.9 ± 1.2

12

Standard Error of Treatment Means= 0.74
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Table 4

Newrnan-Keuls' Multiple Range Test for Corticosterone

Treatment

vs.

Treatment

Difference

Group 3

Group 4

0.49

Group 3

Group 6

2.36

Group 3

Group 1

2.75

Group 3

Group 2

6.31

*

Group 3

Group 5

6.34

*

Group 4

Group 6

1. 86

Group 4

Group 1

2.26

Group 4

Group 2

5.81

Group 4

Group 5

5.85

Group 6

Group 1

0.39

Group 6

Group 2

3.95

Group 6

Group 5

3.98

Group 1

Group 2

3.55

Group 1

Group 5

3.58

Group 2

Group 5

0.03

None of the vehicle-

Sig .05

*
*

or sham-treated experimental groups were

significantly different from the normal corticosterone plasma pool.

CHAPTER V

DISCUSSION

A. Overview
The following conclusions can be drawn from the results presented:
(1) Neurons in the PVN mediate the stress-induced increase in renin and
corticosterone secretion.

(2) Catecholaminergic nerve terminals in the

PVN mediate the effect of stress on renin and corticosterone secretion.
(3) Stress-induced corticosterone secretion appears to be mediated by

~

receptors in the PVN, while (4) stress-induced renin secretion is mediated
by a receptor that is not

~-adrenergic.

Stress-induced renin secretion

may be mediated by a different catecholamine receptor, a neuropeptide or
other substance(s) colocalized in catecholaminergic nerve terminals.

B. Justification of the Stress Paradigm
Abundant

evidence

was

presented

in

the

literature

review

to

demonstrate that renin and corticosterone secretion can be elevated by
many different stressors.

The stress paradigm used in these experiments

was a conditioned fear paradigm that involved exposing the rats to an
initially neutral stimulus (the stress chamber) which was followed after
ten minutes by an aversive stimulus (footshock).

The latter unconditioned

stimulus elicited a range of unconditioned responses, including neuroendocrine

(increased

renin

and

corticosterone

(defecation, urination, freezing) responses.
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levels)

and

behavioral

As the pairings of stimuli
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were continued,

the originally neutral stimulus became a conditioned

stimulus, capable of eliciting the same responses as the unconditioned
stimulus.

1. Classical Conditioning of Fear Stimuli
Classical conditioning can account for the wide range of stimuli
that can produce fear in animals and humans (Watson, 1924).

An experiment

by Hunt and Otis (1953) demonstrated that one symptom of fear, defecation,
can be classically conditioned.

They presented a rat with a flashing

light for three minutes, at the end of which time the animal received an
Eight conditioning trials were run.

electric foot shock.

defecation occurred primarily when the

shock was

At first,

delivered,

but

it

increasingly began to occur during the presentation of the flashing light.

A similar phenomenon was
paradigm used

in the

experiments

observed with
of this

the

conditioned

dissertation.

fear

Behavioral

observations were made throughout the testing procedure, and recorded on
the third and fourth (final) days.

Rats were monitored for defecation

and urination, as well as exploratory, freezing or grooming behaviors.
On the first day, the rats were placed in the stress chamber for a ten
minute interval, at the end of which time they received a mild foot shock.
The rats were tested in this manner for four consecutive days, the only
exception being that on the final day, no foot shock was given.

On the

first day in the stress chamber the rats did not defecate until the time
of the foot shock.

However by the third day (and in some cases the

second), as soon as the rats were placed in the stress chamber they began
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to defecate.

The defecation suggested that the rats had paired the

placement in the chamber with the impending foot shock, supporting the
hypothesis that classical conditioning is an integral part of the ability
of previously neutral stimuli to elicit fear.

Lorens et al.

(1989)

reported the number of fecal boli as a defecation score, a quantitative
measurement of a behavioral response to conditioned fear.
In the experiments of this dissertation,
explored the test chamber and groomed themselves.

the

control animals

The stressed animals,

after the first or second day of conditioning, would sometimes explore,
and sometimes groom, but for the most part would defecate, urinate and
exhibit freezing behavior.
immobility,

and

is

Freezing behavior consists of tense and silent

seen in many

species

in times

of danger.

The

observation of freezing behavior in response to the CS represents another
similarity between my experiments and those presented by Hunt and Otis
(1953).

Normally a rat responds to an electric foot shock with a great

increase in activity - running around frantically, jumping, and trying to
escape the shock.

However, in my experiments and the experiments of Hunt

and Otis

the

(1953),

stimulus

different behavior - immobility.

followed by shock caused a

radically

This is quite an exception to the usual

pattern of the CS (in my case, the stress chamber) eliciting a similar
(though not exact) reaction to that of the UCS (the footshock).

Gray

(1971) suggested the possibility that freezing and more active forms of
escape and avoidance behavior are controlled by separate brain systems,
and represent a combination of learning and innate behavior.
The

process

of

producing

electrolytic

lesions

or

injecting

neurotoxins is an invasive procedure that could, theoretically, interrupt
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fiber pathways that are involved in the learning/conditioning process.
Because

this

surgical

intervention

occurs

two

weeks

prior

to

the

behavioral conditioning paradigm, it is important to look for potential
differences in the behavior of sham or vehicle-injected rats compared with
rats with electrolytic or chemical lesions

in the PVN.

Behavioral

observations during the conditioning process indicated that the lesions
did not prevent defecation, urination and freezing in the stressed rats.
This suggests that the lesions did not interfere with the conditioning
process.

C. Electrolytic and Ibotenic Acid Lesions in the PVN
The data suggest that neurons in the PVN mediate the effect of
stress on renin secretion and confirm results by others (Rivier and Vale,
1983; Dohanics et al., 1986) that neurons in the PVN mediate the effect
of stress on corticosterone secretion.

This conclusion is based on the

finding that both complete electrolytic lesions in the PVN and selective
destruction of cells in the PVN prevented the stress-induced elevation in
plasma

renin activity,

plasma

renin

concentration and plasma

cort-

icosterone levels, whereas electrolytic lesions in the thalamic nucleus
reuniens were ineffective.

Ibotenic acid was selected for its ability to

selectively destroy cell bodies while leaving fibers of passage intact
(Markowska et al., 1985; Winn et al., 1984).

Magnocellular neurons in the

PVN have been reported to be resistant to the neurotoxic effects of kainic
acid (Zhang and Ciriello, 1985).

Herman and Wiegand (1986) have reported

that ibotenic acid selectively destroyed parvocellular neurons in a dosedependent manner while sparing magnocellular neurons.

They reported that
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loss of parvocellular neurons occurred at 0.5, 0.75, 1.0 and 2.0 µg doses
of ibotenic acid.
was

Loss of magnocellular neurons (mostly vasopressinergic)

observed only after

the

2 .0 µg

dose.

Their protocol

involved

unilateral injections (compared to our protocol of bilateral injections)
directed towards the central portion of the PVN at the level of the
posterior magnocellular division.

In our study,

the drug volume was

higher (0.3 µl compared to 0.1 µl) and the injection site had to be at
least 0.5 mm lateral to the midsagittal suture.

Injections of ibotenic

acid closer to the midline led to diffusion of the drug into the third
ventricle, resulting in death of the rats.

We did not observe selective

sparing of the magnocellular neurons after injections of ibotenic acid.
The effect of stress on corticosterone secretion is most likely
propagated by stimulation of CRF neurons in the PVN.

The majority of the

diencephalic CRF-neurons are located in the parvocellular neurons in the
dorsal and medial subnuclei of the PVN (Liposits et al., 1987; Liposits
and Paull, 1985).

A small number of CRF-neurons also are present in the

magnocellular divisions of the nucleus
Piekut and Joseph, 1986).

(Swanson and Sawchenko,

1983;

Dohanics et al. (1986) reported that the full

corticosterone and ACTH response to ether or ether plus laparotomy stress
requires not only an intact PVN, but also an intact neurointermediate
lobe.

Therefore, our data are consistent with the hypothesis that CRF

neurons in the parvocellular PVN are activated during the CER procedure
to stimulate ACTH and thus corticosterone secretion.

Furthermore, the

data with corticosterone support the histological verification of the
accuracy of the lesions in the PVN.

The finding that basal corticosterone

concentration was not altered by the PVN lesions is in agreement with
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previous studies by Meyerhoff et al. (1987) and Makara et al. (1986), who
reasoned that in the absence of CRF input, the cells in the pituitary can
maintain a basal level of ACTH but cannot respond to stimuli which would
increase ACTH secretion.

Similar findings were also reported using CRF

antisera (Nakani et al., 1985; Ono et al., 1985; Rivier et al., 1982).
Nucleus

reuniens

lesions

inhibited

corticosterone but not renin secretion.

the

effect

of

stress

on

This suggests that fibers which

course through the nucleus reuniens and innervate the CRF neurons in the
PVN may have been disconnected by this lesion.

Since no inhibition of

stress-induced renin secretion occurred in these rats, the data suggest
that the fibers, and possibly cells, which mediate the effect of stress
on renin secretion are different from the fibers and cells which mediate
stress-induced corticosterone secretion.
The nature of the PVN neurons which mediate the effect of stress
on renin secretion is not known.

It is clear, both from the present

results and from studies by Porter (1988), that cells in the PVN play an
important role in the regulation of renin secretion.

Electrolytic lesions

in the PVN prevent the increase in plasma renin activity after injection
of the serotonin releasing drug p-chloroamphetamine (Gotoh et al., 1987).
Furthermore,

these lesions also prevent the increase in plasma renin

activity that follows

immobilization stress,

although a reduction in

plasma renin substrate (angiotensinogen) levels could account for this
effect (Gotoh et al., 1987).

It is important to note that, in the present

study, a saturating concentration of exogenous renin substrate was added
in the plasma renin concentration assay to control for possible variation
of renin substrate in the plasma samples from the experimental rats.

In
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contrast, the plasma renin activity assay was a measure of the production
of angiotensin I from endogenous renin, combined with endogenous renin
substrate.

Since plasma renin activity and concentration were equally

affected by the lesions, the changes were clearly due to changes in renin,
not renin substrate concentration in plasma.
D. Injection of 6-0HDA into the PVN
The main conclusion of the 6-0HDA experiment is that catecholaminergic nerve terminals in the PVN mediate the effect of stress on both renin
and corticosterone secretion.
that

This conclusion is based on the observation

injection of 6-0HDA into

the

PVN

inhibited the

increase in renin and corticosterone secretion.

stress-induced

6-0HDA is a neurotoxin

that is taken up by the catecholaminergic nerve endings and produces
degeneration of the nerve terminals (Breese and Traylor, 1970; Uretsky and
Iversen, 1970).
gic neurons.

6-0HDA is considered to be selective for catecholaminer-

Uretsky and Iversen (1970) reported that doses of 6-0HDA

that decreased brain norepinephrine and dopamine levels did not affect
brain serotonin or GABA.

Shor-Posner et al.

(1986) have reported that

injection of 6-0HDA into the PVN, in the same dose as in my experiment,
produced a 75% reduction in norepinephrine, 56% reduction of epinephrine
and 47% reduction in dopamine concentration in the PVN.

The catechol-

amines were determined by HPLC and electrochemical detection.
cal

analysis

also

revealed a

fluorescence in the PVN.

significant

decrease

in

Histochemi-

catecholamine

This study suggests that 6-0HDA can cause a

degeneration of noradrenergic, adrenergic and dopaminergic elements in the
PVN.

Further support was provided by Fety et al. (1984), who injected 6-

0HDA into the fourth ventricle of rats to study the biochemical reponses
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of the adrenergic (Cl, C2) cell groups versus the noradrenergic (Al, A2
and A6) cell groups.

Their results indicated that the adrenergic cell

groups are sensitive to the neurotoxic effects of 6-0HDA since they
exhibited changes in tyrosine hydroxylase and dopamine-&-hydroxylase in
a similar manner to the noradrenergic cell groups.
In the 6-0HDA experiment of this

dissertation,

norepinephrine

depletion was verified immunocytochemically by using an antibody for
dopamine-&-hydroxylase. No attempt was made to differentiate between loss
of norepinephrine-, dopamine- or epinephrine-containing nerve terminals.
Consequently, these results cannot indicate which catecholamine mediates
the effects of stress on renin or corticosterone secretion.
The suggestion that catecholaminergic nerve terminals in the PVN
mediate stress-induced corticosterone secretion is supported by studies
involving the ventral noradrenergic bundle (VNAB), which conveys most of
the noradrenergic (Moore and Bloom, 1979; Palkovits, 1981; Swanson and
Sawchenko, 1980) and adrenergic (Ungerstedt, 1971) afferents to the PVN.
Injections of 6-0HDA into the VNAB inhibited the ACTH stress response
(Szafarczyk et al. ,

1985),

secretion

photic,

following

prevented the
acoustic

and

increase

in corticosterone

sciatic

nerve

stimulation

(Feldman et al., 1988), and significantly reduced CRF levels in hypophysial portal blood (Guillaume et al., 1987).

In addition, Feldman et al.

(1986) demonstrated that 6-0HDA injections into the PVN significantly
inhibit

the

stimulation.

adrenal

response

to

photic,

acoustic and sciatic nerve

Together, these results suggest a role for catecholaminergic

afferents to the PVN in the activation of adrenocortical responses to
stress.
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The dorsal noradrenergic bundle

(DNAB)

mediator of stress-induced renin secretion.

may play a

role as a

Some afferent fibers from

the locus coeruleus travel to the PVN in the DNAB (Kobayashi et al., 1975;
Loizou, 1969).

Lightman et al. (1984) demonstrated that injections of 6-

0HDA into the DNAB markedly attenuate

the

increase

in plasma renin

activity in response to hemorrhage, while injections of 6-0HDA into the
VNAB had no effect.

This study, in combination with my results, suggests

that catecholaminergic afferents to the PVN mediate the renin response to
stress.

E. Injection of Sotalol into the PVN
Since the data suggest that catecholaminergic nerve terminals in
the PVN mediate the stress-induced increase in renin and corticosterone
secretion, the next question to address was whether or not E-adrenergic
receptors mediate this effect.
adrenoceptor

antagonist

Previous studies demonstrated that the &-

propranolol

(1

mg/kg,

i.p.)

significantly

attenuated the stress-induced increase in plasma renin activity (Van de
Kar et al., 1985).

Since propranolol is known to cross the blood-brain

barrier (Garvey and Ram, 1975; Lemmer et al., 1985), and the PVN contains
a high concentration

of~

receptors (Wanaka et al., 1989), it is possible

that a E-receptor, located in the PVN, could be involved in mediating the
effect of stress on renin and corticosterone secretion.
experiment,

In the present

sotalol was selected instead of propranolol because it is

devoid of local anesthetic activity and is both a &1 and E2 antagonist
(Fitzgerald, 1984).

Injection of sotalol into the PVN prevented the

stress-induced increase in corticosterone secretion but did not prevent
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the stress-induced increase in renin secretion.

This suggests that a &-

adrenergic receptor in the PVN plays a role in the corticosterone response
to

stress.

However,

many

B-adrenoceptor

antagonists

serotonin receptors in the brain (Conway et al., 1978).

also bind

to

Since only one

dose of sotalol was administered, it is possible that this dose (15 nmol)
could affect serotonergic as well as B-adrenergic receptors.

Other

investigators have injected much higher doses of sotalol and propranolol
in the brain.

Injections of sotalol (400 nmol) or propranolol (120 nmol)

into the perifornical region of the anterior hypothalamus did not prevent
the feeding response induced by either epinephrine (20 nmol) or norepinephrine (20 nmol).

This feeding response was prevented by injections of

the a-adrenoceptor antagonists phentolamine (30 or 60 nmol), tolazoline
(100 nmol)

or phenoxybenzamine

(Leibowitz, 1975).

(15 nmol)

in

the

same brain region

Injection of propranolol (116 nmol) or timolol (95

nmol) into the cerebral ventricles prevented the effect of air stress on
renal sympathetic nerve activity in spontaneously hypertensive rats.
addition,

icv

injection of propranolol

(4

or

25

nmol)

In

produced an

inhibition of epinephrine-stimulated ACTH release (Szafarczyk et al.,
1987).

In my study, the fact that sotalol inhibited the stress-induced

increase in corticosterone secretion but not the stress-induced increase
in renin secretion argues for a relative selectivity in receptor binding.
Other investigators have provided evidence for the role of &receptors in the regulation of corticosterone secretion.

Szafarczyk et

al. (1987) demonstrated a stimulatory role for epinephrine and norepinephrine

on corticosterone release.

Injection

(icv)

of epinephrine or

norepinehrine induced ACTH release comparable to that occuring under
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(ether)

stress

norepinephrine

conditions.
on

an

Epinephrine

equimolar

basis.

was

more

efficacious

The

stimulating

than

effect

norepinephrine was reversed by icv pretreatment with prazosin,

of

an a 1

antagonist, whereas the effect of epinephrine was inhibited by either
These results

prazosin or propranolol.

suggest

that norepinephrine

stimulates ACTH release via a 1 receptors, whereas epinephrine acts via both
a 1 - and &-adrenoceptors.
receptors

In vitro studies support the role of &-adrenergic

in CRF release.

Norepinephrine stimulated the release of

immunoreactive CRF from cultured neonatal rat hypothalamic cells.
effect was blocked by propranolol but not by prazosin.

This

In addition, the

E.-adrenoceptor agonist isoproterenol significantly increased CRF while the
a-adrenoceptor agonist phenylephrine was
concentrations (Widmaier et al., 1989).

ineffective,

except at high

Together, these data strongly

suggest a stimulatory role for &-receptors in the regulation of corticosterone secretion.
To speculate as to which neurotransmitter could be involved in
mediating the effect of stress on corticosterone
studies should be considered.

secretion,

several

Leibowitz et al. (1986) demonstrated that

norepinephrine injections into the PVN dose-dependently increased serum
corticosterone levels, while dopamine had no effect.

Epinephrine in the

PVN was even more efficacious than norepinephrine in increasing serum
corticosterone

levels.

Further,

a

study by Spinedi

et al.

(1988)

demonstrated that central inhibition of phenylethanolamine-N-methyltransferase (PNMT), producing a selective decrease in hypothalamic epinephrine
levels, significantly decreased the plasma ACTH response to ether stress,
and at later times also caused a selective decrease in CRF content.

These
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results

support a

stimulatory role of central epinephrine-containing

neurons in CRF release.

Sawchenko et al. (1987) estimated that at least

40% of the retrogradely- labeled catecholaminergic cell groups that project
to the PVN could be adrenergic (PNMT-immunoreactive).

These results

suggest that stress-induced increases in corticosterone levels could be
mediated via adrenergic nerve terminals activating B-receptors in the PVN.
Stress-induced increases in plasma renin activity and concentration
are mediated by a different receptor.

It is possible that an a-adrenergic

receptor could mediate the stress-induced increase in renin secretion.
However,

pharmacological studies suggest that activation of brain a 2-

adrenoceptors lowers renin secretion by inhibiting sympathetic outflow to
the kidneys.

Injection of clonidine (icv) prevented the air jet stress-

induced increase in renal sympathetic nerve activity in spontaneously
hypertensive rats.

This effect was reversed by icv injection of the a 2-

adrenergic antagonists yohimbine and rauwolscine
1986).

(Koepke and DiBona,

!CV injection of clonidine lowered plasma renin activity at a dose

which is ineffective when given intravenously (Reid et al., 1975).
et

al.

(1977)

demonstrated

that

administration

of

L-DOPA

to

Blair
dogs

pretreated with the peripheral decarboxylase inhibitor carbidopa results
in a drop in blood pressure and an inhibition of renin secretion.

Since

this treatment increases brain catecholamine content, the results suggest
that catecholamines formed from L-DOPA can act within the central nervous
system to cause a decrease in renin secretion.

In this study the decrease

in plasma renin activity was dependent upon the presence of the renal
nerves.

These studies suggest that central a 2 -adrenoceptors are involved

in decreasing renin secretion.

However, it is possible that central a 1 -
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adrenoceptors
secretion.

could

mediate

the

stress-induced

increase

in

renin

Ganong et al. (1982) suggested that the activation of central

a 1 receptors increases renin secretion in anesthetized dogs.

However,

these data are not very convincing since they only reported renin values
following icv injection of the a 1 -agonists methoxamine and phenylephrine,
without the appropriate vehicle controls.
The PVN has been shown to project to those segments of the thoracic
cord containing sympathetic preganglioninc neurons innervating the kidney
(Swanson and Mc Kellar, 1979).

Other studies have suggested that the

sympathetic nervous system mediates the stress response from the brain to
the kidney (Golin et al., 1988).

However, in our laboratory, (see STRESS:

Effect of Peripheral Sympathectomy) sympathectomized-adrenal enucleated
rats showed no inhibition of the stress-induced increase in plasma renin
activity/concentration or plasma corticosterone levels (Richardson Morton
et al., 1988).

This suggests that the sympathetic nervous system and

adrenal catecholamines are not the only mediators of the stress-induced
increase in renin secretion.

An alternate theory is that cell bodies in

the

secrete

PVN

are

stimulated to

a

renin-releasing

factor

to

the

bloodstream to promote renin release from the kidneys (Van de Kar et al.,
1987).
If a

and~

receptors in the PVN do not mediate stress-induced renin

secretion, another possibility is that a neuropeptide, coreleased at the
catecholaminergic nerve terminals in the PVN, mediates stress-induced
renin

secretion.

A likely

candidate

is

neuropeptide

Y,

which

is

coexpressed in noradrenergic and adrenergic brain stem cell groups and is
present

in noradrenergic

and adrenergic nerve

terminals

in the

PVN
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(Sawchenko et al.,

1985).

Intraventricular injection of NPY has been

shown to increase plasma ACTH and corticosterone secretion (Harfstrand et
al., 1987) and plasma angiotensin II levels (Harfstrand et al., 1986).
However, Fuxe et al. (1983) reported that intracisternal injection of NPY
causes

hypotension,

which

could

also

increase

renin

secretion

by

activation of the intra-renal stretch receptor (Fahri et al., 1982).
Yet

another

neuropeptide

of

interest

is

galanin,

due

to

its

preferential coexistance with noradrenergic cell groups that project to
the PVN.

Combined immunohistochemical-retrograde transport studies have

demonstrated
hydroxylase
evidence

galanin-immunoreactivity
immunoreactivity

for

galanin

in the

coexistence

neurons that project to the PVN.
anterior,

periventricular,

dorsal

coexisting

Al

in

and A6

with

cell

adrenergic

dopamine-&-

groups,

with no

(PNMT-immunoreactive)

Galanin inputs were confined to the
and

ventral

subdivisions

of

the

parvocellular PVN, with only a sparse projection to the oxytocinergic
neurons of the magnocellular division of the PVN (Levin et al, 1987).

F. Hypothetical Organization of Brain Pathways Mediating
Stress-Induced Renin and Corticosterone Secretion
The

neural

pathways

mediating

stress-induced

renin

and

cort-

icosterone secretion are likely to be complex and multi-synaptic, due to
the many inputs which must be integrated.
component

that

arises

during behavioral

First,

there is a

conditioning.

sensory

When the

rat

receives the foot shock as part of the conditioned fear paradigm,

the

sensory message is transmitted from the nerve fibers in the skin to the
spinal cord, where it travels in the lateral spinothalamic tract to the
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posteroventral nuclei of the thalamus.

The spinothalamic fibers are

accompanied by fibers that terminate in the reticular formation (spinoreticular) and the periaqueductal gray and tectum (spinotectal).

The

periaqueductal grey has been shown to play a role in flight or defensive
behavior (de Molina and Hunsperger, 1962).
The pain input route most
reticular

formation,

hippocampus.
reception.

through the

likely continues
thalamus,

from

to reach

the midbrain

the

septum and

The septo-hippocampal system plays a major role in pain
The hippocampus emits a theta wave (4-9 cps rhythm) as a

response to a painful stimulus in the rat, and in the emotional states of
disappointment and frustration in humans.

Lesions in the medial nuclei

of the septum and the thalamic nucleus centrum medianum abolish the theta
wave emitted by the hippocampus in response to a painful stimulus (Gray,
1971).
Damage to the hippocampus has been shown to facilitate acquisition
of shuttle box avoidance (Green et al., 1967; Van Hoesen et al., 1972)
possibly due to a deficit in a behavioral inhibitory system (Douglas,
1967; Gray, 1982).

These studies, and others (Squire and Zola-Morgan,

1983), suggest a critical role of the hippocampal formation in learning
and memory. The hippocampal formation and septa! region share extensive
bidirectional connections.

The lateral, medial and posterior divisions

of the septa! regions are associated with the hippocampal formation while
the ventral division (bed nuclei) is primarily related to the amygdala
(Swanson et al., 1987).

The subicular complex and the entorhinal area of

the hippocampus receive an extensive sensory input from the cortex,
including olfactory,

visual,

auditory and somatosensory.

Additional
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sensory information is relayed through two routes, one via the thalamus,
extrahippocampal cortex and amygdala and the other via ascending pathways
from the brainstem and basal forebrain.

The hippocampus also receives

considerable serotonergic input from the raphe nuclei (Azmitia, 1978;
Lorens and Guldberg, 1974; Steinbusch, 1981).

Immunoreactive-CRF neurons

have been demonstrated in the hippocampus (Swanson, 1983).

However, the

axonal projections of these cells are relatively short, suggesting that
they might function as interneurons (Kohler, 1986).
The

hippocampus

has

many

interconnections

structure, the amygdala (Krettek and Price, 1978).

to

another

limbic

The amygdaloid complex

has been shown to be involved in the regulation of fear-motivated behavior
(Blanchard and Blanchard, 1972; Spevack et al.,

1975).

The amygdala

appears to play a role in the stress response via the pituitary-adrenal
cortical axis .
contains

large

The central nucleus of the amygdala,
numbers

of CRF-containing

(Swanson et al., 1983; Moga and Gray, 1985).

cell bodies

in particular,
and

terminals

Both the central and medial

amygdaloid nuclei project to the thalamic nucleus reuniens (Aggleton and
Mishkin, 1984).

This helps to explain why lesions in the nucleus reuniens

prevented the effect of stress on corticosterone secretion.
Most amygdaloid nuclei project to the bed nucleus of the stria
terminalis

(BNST) and the hypothalamus.

Since the hypothalamus also

receives a substantial projection from the BNST,

there exists a di-

synaptic route for the amygdala to modulate hypothalamic function (Krettek
and Price, 1978).

The BNST also receives fibers from the dorsal and

median raphe nucleus (Azmitia and Segal, 1978), as well as a massive
projection from the hippocampus (Swanson and Cowan, 1977).

To summarize,
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the incoming sensory information and "learning"/associative processes that
accompany the conditioned fear paradigm are likely conveyed to the PVN via
limbic regions of the telencephalon since direct neocortical projections
to the hypothalamus cannot be demonstrated (Swanson et al., 1987).

The

hippocampus, amygdala and ventral septal region project heavily to the
BNST, which in turn projects to the CRF regions of the PVN.

The question

that remains is: how does this input to the PVN become integrated with the
direct nordrenergic (A2) and adrenergic (Cl-C3) input via the VNAB (brain
stem to the CRF neurons in the PVN)?

Swanson et al.
tract,

which

(1983) suggested that the nucleus of the solitary

receives

(Beckstead and Norgren,

direct

vagal

and

glossopharyngeal

afferents

1979) could serve as a major relay point of

visceral sensory information to CRF cell bodies in the basal forebrain.
Likewise the parabrachial nucleus, which receives a large input from the
NTS (Norgren, 1978), and the locus coeruleus also project to many of the
sites

that

contain

CRF-immunoreactive

cell

bodies,

including

the

parvocellular PVN, the bed nucleus of the stria terminalis and the central
nucleus of the amygdala.

As mentioned above, these nuclei may also be

involved in the relay of visceral sensory information to CRF cell bodies
(Swanson et al., 1983).

This hypothetical pathway could provide a direct

stimulus for corticosterone secretion.
Another possibility is that the noradrenergic input to the PVN is
serving as a neuromodulator to "set a bias" to amplify or buffer incoming
stimuli to the cells.

Even though norepinephrine might have little effect

on the resting excitability of the CRF neurons, it could have profound
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effects on the amount of CRF released following an action potential
(Nicoll, 1982).
before

For example, pretreatment with norepinephrine (5 µ.M)

iontophoretically-applied

glutamate

(50

nA)

in

a

pyramidal

(hippocampal) cell has been shown to evoke a higher frequency and longer
duration

train of action potentials

than

following

glutamate

alone

(Madison and Nicoll, 1986).
Wallace et al. (1989) demonstrated that the amygdala innervates the
locus

coeruleus

(A6)

adrenergic cells.

and NTS

(A2)

noradrenergic

cells,

and the

C2

Most of the rostral A6 and A2 neurons had amygdaloid

terminal contacts.

This pathway could be involved in integrating the

sensory/associative

processes

with

the

stimulatory

catecholaminergic

afferents to the PVN.
The possibility exists that serotonergic neurons play a role in
transmitting the stress stimulus.

The dorsal raphe nucleus (B7) is one

of the nine 5-HT cell groups originally described by Dahlstrom and Fuxe
(1965), which innervates the forebrain.

Studies from our laboratory have

shown that electrolytic lesions in the dorsal raphe nucleus prevent the
stress-induced increase in plasma renin activity using a three-minute CER
(Van de Kar et al., 1984).

This experiment was repeated, extending the

CER to ten minutes so that corticosterone levels could be evaluated.
Confirming the previous results, we found that electrolytic lesions in the
dorsal raphe nucleus prevented the stress - induced increase in plasma renin
activity and concentration and corticosterone levels (Richardson Morton
et al., 1986).

There could be a connection between the fact that both

dorsal raphe lesions and PVN lesions prevent the stress-induced increase
in plasma renin activity, plasma renin concentration and corticosterone
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levels.

Sawchenko et al.

(1983) have demonstrated that serotonergic

neurons in the midbrain (especially the dorsal raphe) innervate the PVN.
Although the serotonergic fiber density in the PVN is low compared with
immediately surrounding areas,

there is a distinct projection to the

medial parts of the parvocellular division.

Liposits et al. (1987) have

demonstrated by electron microscopic methods

that serotonergic nerve

terminals innervate CRF-immunoreactive parvocellular cells in the PVN.
Injections (i.p.) of the 5-HT2 antagonist, LY53857, did not prevent
the

stress-induced

increase

(Richardson Morton et al.,

in

renin

1986).

or

However,

corticosterone

secretion

injection of the 5-HT 1A

agonists buspirone and ipsapirone significantly attenuated the stressinduced increase in plasma renin activity, plasma renin concentration and
corticosterone levels (Urban et al., 1986; Van de Kar et al., 1985; Lorens
Both buspirone and ipsapirone inhibit the firing of

et al. , 1989).

serotonergic neurons in the dorsal raphe (Basse-Tomusk, 1986; VanderMaelen
et al., 1986).

Thus, serotonergic neurons in the dorsal raphe nucleus

could be involved in stress-induced renin and corticosterone secretion.
There are fiber projections from the locus coeruleus to the dorsal raphe
nucleus (Cowan and Park, 1986), with direct noradrenergic nerve terminal
innervation of serotonin nerve cells in the dorsal raphe (Baraban and
Aghajanian, 1981), and projections from the dorsal raphe to the locus
coeruleus (Conrad et al., 1974).

These interconnections could provide a

relay for the noradrenergic bundles to influence hypothalamic neuroendocrine responses.
Another possibility is that the dorsal raphe serotonergic neurons,
which also project to the hippocampus (Swanson et al., 1987), provide a
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tonic inhibition of the "behavioral inhibition" system of the hippocampus.
In this case, administration of 5-HT 1A anxiolytic agents or electrolytic
lesions in the dorsal raphe nucleus would decrease the input to the septohippocampal system, thus reducing the activity of the septo-hippocampal
behavioral

system,

ultimately decreasing

the behavioral

and possibly

neuroendocrine stress response (Kuhar, 1986).
Clearly,

the neural pathways mediating stress-induced renin and

corticosterone
dissertation,

secretion are
it

can be

complex

and multi-synaptic.

concluded that

From

this

stress-induced corticosterone

secretion appears to be mediated by Preceptors in the PVN, while

stress-

induced renin secretion is mediated by a receptor that is not P-adrenergic.

Stress- induced renin secretion may be mediated by a

different

catecholamine receptor, a neuropeptide or other substance(s) colocalized
in catecholaminergic nerve terminals.
The following figure is a schematic diagram of the hypothetical
brain

pathways

secretion.

mediating

stress-induced

renin

and

corticosterone
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FIGURE 24

Hypothetical Brain Pathways Mediating
Stress-Induced Renin and Corticosterone Secretion

~
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